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 Prolonged exposure to hypoxia due to high altitude or pulmonary diseases like 
chronic obstructive pulmonary disease causes chronic hypoxia-induced pulmonary 
hypertension (CHPH), which results in right heart hypertrophy, worsens the prognosis of 
the underlying pulmonary diseases, and even death. Chronic hypoxia (CH) impacts 
various targets in the pulmonary vasculature such as pulmonary artery (PA), leading to 
complex physiologic responses during the development of CHPH. It is well established 
that CH alters calcium (Ca2+) homeostasis in pulmonary arterial smooth muscle cells 
(PASMCs) due to the enhancement of extracellular Ca2+ influx as the result of changes in 
the expression and activities of various membrane channels, transporters, and exchangers. 
However, the evidence for alterations of intracellular Ca2+ release in PASMCs caused by 
CH is scanty to date.  
 CD38 is a multifunctional enzyme that synthesizes the endogenous Ca2+ 
mobilizing messengers cyclic adenosine diphosphate-ribose (cADPR) and nicotinic acid 
adenine dinucleotide phosphate (NAADP), which are potent regulators of Ca2+ release 
via ryanodine receptor (RyR)-gated sarcoplasmic reticulum and NAADP-sensitive 
endolysosomal Ca2+ stores, respectively. CD38 is thought to play important roles in 
[Ca2+]i regulation via Ca
2+ release, contributing to diverse physiologic responses in many 
different cell types.  However, its functions and regulatory mechanisms in PASMCs are 
still unclear. In particular, there is no systematic study on the mechanism of agonist-
induced activation of CD38 in PASMCs. Furthermore, the effect of CH on CD38-
dependent Ca2+ release in PASMCs has not been examined. The objective of this thesis 
research is to examine systematically the mechanism of agonist-induced CD38 activation 
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and the CH-induced alteration of CD38 expression and activity in PASMCs, as to provide 
novel insight into the contribution of CD38 in the development of CHPH. 
 The first part of this thesis research determined the expression of CD38, and its 
roles in angiotension II (Ang II)-induced vasoconstriction in PAs, and Ang II-induced 
Ca2+ release (AICR) in PASMCs. Examination of the expression profile of CD38 in 
various rat arteries indicates a relatively high level of CD38 expression in PA smooth 
muscle and PASMCs. Application of Ang II to PASMCs elicited Ca2+ response 
composed of both extracellular Ca2+ influx and intracellular Ca2+ release AICR activated 
in the absence of extracellular Ca2+ was significantly reduced by pharmacological or by 
siRNA inhibition of CD38, implying that CD38 mediates AICR in PASMCs.  AICR was 
suppressed by the cADPR antagonist cADPR 8-Br-cADPR or the inhibition of the RyR-
gated Ca2+ released with ryanodine.  It was also suppressed by the NAADP-antagonist 
Ned-19 or the disruption of endolysosomal Ca2+ stores by the vacuolar H+-ATPase 
inhibitor bafilomycin A1. Suppression of AICR by the inhibition of cADPR- and 
NAADP-dependent pathways was non-additive, indicating inter-dependence between 
RyR- and NAADP-gated Ca2+ release in PASMCs. Furthermore, AICR was inhibited by 
the protein kinase C (PKC) inhibitor staurosporine, the non-specific NADPH oxidase 
(NOX) inhibitor apocynin and DPI, the NOX2 specific inhibitor gp91ds-tat, and the 
reactive oxygen (ROS) species scavenger TEMPOL. These results provide direct 
evidence that Ang II activates CD38-dependent Ca2+ release via the PKC-NOX2-ROS 
pathway in PASMCs. 
 The second part of the research characterized the CH-induced alterations in the 
expression and functions of CD38 in PASMCs. The expression of CD38 protein and 
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mRNA were both significantly upregulated in the PA smooth muscle of CH rats. The 
upregulation of CD38 in PA of CH rats was time-dependent, observed after 3–7 days of 
hypoxic exposure and declining after 3 weeks of CH. NADase activity of CD38 in PA 
smooth muscle was significantly increased, whereas the activity in whole lung was 
decreased after 1-week hypoxia, suggesting specific CD38 upregulation in hypoxic PA. 
AICR was significantly increased in PASMCs of CH rat. The CH-induced enhancement 
in AICR was completely vanished by the inhibition of CD38, indicating that CH triggers 
augmentation of CD38 activity in PASMCs.  The CH-induced upregulation of CD38 
expression and activity were due to the direct effect of hypoxia on PASMCs. In vitro 
exposure of PASMCs from normoxic rats to hypoxia caused significant increase in CD38 
expression and enhancement in AICR, which was abolished by the inhibition of CD38 
activity. Moreover, the CH-induced upregulation of CD38 expression in PASMCs was 
inhibited by calcineurin/NFAT inhibitors, indicating that CH induces CD38 upregulation 
in PASMC mediated by the calcineurin/NFAT-pathway. Furthermore, the NAADP-
dependent Ca2+ channel TPC1 and TPC2 was increased in CH rat PA. Hence, these 
results suggest that CH increases the expression and activity of CD38 and the CD38-
dependent Ca2+ release in PASMCs. 
 Collectively, the results indicate the CH-induced enhancement of CD38 
expression and activity in PASMCs may contribute to the alteration of Ca2+ homeostasis 
in PASMCs. It also implies that CD38 could be a possible therapeutic target for the 
treatment of this dreadful disease. 
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BACKGROUND AND INTRODUCTION: 
OVERVIEW OF CALCIUM REGULATION  
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I. Overview of Ca2+ 
   A. Ca2+ homeostasis 
 Ca2+ plays a pivotal role in the regulation of a wide spectrum of physiological 
functions including cell proliferation, differentiation, membrane trafficking, secretion, 
apoptosis, regulation of endo- and exocytosis, enzyme activity, fertilization, innate 
immunity, gene transcription, progression of cell cycle, and cell contraction 
[1,2,3,4,5,6,7,8]. Resting intracellular Ca2+ concentration ([Ca2+]i) is tightly regulated and 
maintained at approximately 100 nM in skeletal muscle, cardiac muscle, and vascular 
smooth muscle [9,10,11], whereas the concentration of extracellular Ca2+ is 
approximately 1.1 to 1.5 mM [12]. This huge gradient is maintained by energy-
consuming pumps and ion exchangers on the innately ion-impermeable lipid-bilayer 
plasma membrane and intracellular organelle membrane [13]. Because of this Ca2+ 
gradient across the membrane, the regulation of [Ca2+]i depends on many different types 
of extracellular Ca2+ influx and intracellular Ca2+ release pathways, as well as Ca2+ 
removal and uptake pathways [14]. Further, the intracellular Ca2+ signals are 
compartmentalized into local and global Ca2+ signals with specific spatial/temporal 
properties to regulate the effectors in various subcellular compartments and activate 
different Ca2+-dependent physiological processes.  
 
   B. Ca2+ mobilization  
 There are two major mechanisms for increasing [Ca2+]i levels: Ca
2+ entry from 
extracellular fluid and intracellular Ca2+ release from a variety of cellular organelles such 
as endoplasmic or sarcoplasmic reticulum (ER/SR), endolysosomes, mitochondria, and 
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the nuclear envelope [7,15,16,17]. The opening of Ca2+-permeating channels in the 
plasma membrane and the organelle membranes leads to gradient-driven Ca2+ 
mobilization into the cytoplasm. Subsequently, cytoplasmic Ca2+ is rapidly removed or 
taken up via different types of exchangers and energy-consuming ATPases on the plasma 
or organelle membranes to restore resting [Ca2+]i [7]. The general overview of the 
intracellular Ca2+ regulatory mechanism is described in Fig. 1. 
 In smooth muscle cells, elevation of [Ca2+]i is essential for cell contraction. Ca
2+ 
binds to calmodulin to form Ca2+-calmodulin complex, leading to the activation of 
myosin light chain kinase. Myosin light chain kinase facilitates actin-myosin cross-bridge 
 
 
Figure 2.1. Overview of Ca2+ mobilization in cell   Ca2+ homeostasis is maintained 
by ATPases (PMCA and SERCA) and exchangers in plasma or organelle membrane. 
Ca2+ mobilization is gradient-driven across the cellular and organelle membrane via 
Ca2+ permeable channel on membrane. (Abbreviation: PMCA, plasma membrane Ca2+ 




formation by phosphorylation of serine residue in myosin light chain, leading to the 
contraction of smooth muscle cells [18,19,20]. Thus, the regulatory mechanism of [Ca2+]i 
is crucial to the physiological functioning of the vasculature. In this chapter, two 
regulatory mechanisms of Ca2+ mobilization—(a) Ca2+ influx from extracellular space 
and (b) Ca2+ release from intracellular Ca2+ stores to cytoplasm—will be reviewed 
focusing on Ca2+-permeable channels with an emphasize on pulmonary arterial smooth 
muscle cells (PASMCs). 
 
 1. Ca2+ influx pathways in PASMCs 
 Activation of Ca2+-permeable channels on the plasma membrane allows Ca2+ 
influx due to the large Ca2+ gradient (high Ca2+ outside and low Ca2+ inside). A variety of 
Ca2+-permeable channels exist in the cell membrane. They can be categorized as either 
voltage-dependent or voltage-gated Ca2+ channels (VDCCs/VGCCs) or voltage 
independent Ca2+ channels [21,22]. Furthermore, channels for other ions, such as K+ and 
Cl-, are required for maintaining and modulating Ca2+ mobilization.  
 
   a. Voltage-dependent (gated) Ca2+ channels (VDCCs/VGCCs) 
 The open-state and closed-state of VDCCs are dependent on the voltage gradient 
across the plasma membrane, which is referred as membrane potential. At the resting 
membrane potential, VDCCs in PASMCs are mainly in the closed-state, and exhibit 
minimal spontaneous activity [23]. Membrane depolarization activates VDCCs and Ca2+ 
influx, leading to various vascular response including pulmonary vasoconstrictions 
[24,25] and myogenic tones [26,27]. Beside the open/closed-state, VDCC can transition 
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from the open-state to the inactivated-state (different from closed-state), which occurs 
slowly in a voltage and time-dependent manner [28]. 
 Based on the voltage dependence, VDCCs in PASMCs are classified into two 
subtypes, the high-voltage activated L-type Ca2+ channel, and the low voltage-activated 
T-type Ca2+ channel. L-type Ca2+ channels are activated at a threshold potential of 
approximately -40 to -50 mV and T-type VDCCs are activated at a lower membrane 
potential of -60 to -70 mV [29,30]. L-type Ca2+ channels have a relatively slower 
inactivation compared to the T-type Ca2+ channels, and contribute to high-K+-induced 
contraction [29,30,31], and hypoxic pulmonary vasoconstriction [32,33]. Although it had 
been little known about T-type Ca2+ channels in PASMCs, recent studies suggested that it 
may control proliferation [30,34] and contribute to the  development of lung disease such 
as chronic hypoxia-induced pulmonary hypertension (PH) [35].  
 
   b. Voltage-independent Ca2+ channels 
     (1)  Transient receptor potential channels 
 Transient receptor potential (TRP) channels are voltage-independent cation 
channels, which play important roles for Ca2+ entry, particularly in vascular smooth 
muscle cells. TRP channels are consisted 7 subfamilies, namely canonical (TRPC), 
vanilloid-related (TRPV), melastatin-related (TRPM), ankyrin (TRPA), polycystin-
related (TRPP), mucolipin-related (TRPML) and no mechanoreceptor potential C (TRPN 
or nompC)  subfamilies [21,36]. All TRP channels have a structural similarity for six 
transmembrane domains, a pore-forming loop between the fifth and sixth transmembrane 
domain with highly conserved TRP domains. TRP channels operate as specific Ca2+ 
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pathways responsive to a variety of stimuli such as depletion of Ca2+ store, ligand-
receptor activation, and mechanical stress by formation of homogenic or heterogenic 
tetrameric structure [21]. TRPC, TRPV, and TRPM channels have been identified in 
pulmonary arterial smooth muscle and several members of TRP subfamilies such as 
TRPC 1/6 and TRPV4 are crucially associated with the enhancement of myogenic tone 
and agonist-induced vasoreactivity in pulmonary vasculature under prolonged hypoxic 
exposure [21,37,38]. 
 The physiologic functions of TRP channels vary depending on the specific 
subtypes in PASMCs. In particular, TRPC1/4 plays a role in Ca2+ influx as a store-
operated Ca2+ channel and TRPC3/6 as a receptor-operated Ca2+ channel [21]. TRPV4 is 
the most abundant member of TRPV subfamily and one of the mechanosensitive Ca2+ 
channels, which is activated by mechanical stress such as stretch, and plays a crucial role 
for the development of  elevated pulmonary arterial pressure in response to prolonged 
hypoxic exposure [39].  
 
     (2)  Receptor-operated Ca2+ entry 
 Receptor-operated Ca2+ entry (ROCE) occurs via Ca2+ permeating channels, 
which are activated as the result of the binding of agonists to their receptor. Activation of 
ROCE does not require membrane depolarization. ROCE can be activated via G-protein-
coupled receptors (GPCRs), receptor tyrosine kinases (RTK) and guanylyl cyclases as 
well as the direct interaction with signaling molecules such as trimeric G proteins and 
polyunsaturated fatty acids (i.e. arachidonic acid)  [40,41]. Activation of receptors such 
as GPCRs increases the synthesis of the second messengers including inositol-1,4,5-
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triphosphate (IP3), and diacylglycerol (DAG), by phospholipase C (PLC). Indeed, it has 
been reported that various TRP channels play a pivotal roles in ROCE as the channels 
activated by those signaling molecules. Particularly, previous studies have indicated that 
several members of TRPC subfamily such as TRPC3/6 in PASMCs might play the role of 
ROCE, contributing to increase in [Ca2+]i [21,42,43]. 
 Ca2+-sensing receptor (CaSR) is a unique type of GPCRs coupled with PLC, 
contributing to Ca2+ mobilization in PASMCs [44]. Particularly, CaSR is another novel 
candidate in the progression of pathophysiologic states such as PH development by 
modulating Ca2+ entry [44,45]. Yamamura et al. demonstrated that the elevation of 
extracellular Ca2+-induced resting [Ca2+]i in PASMCs from idiopathic PH patient was 
prevented by the antagonist of the CaSRs [45]. Moreover, the expression of CaSRs in PA 
from monocrotaline (MCT)-induced pulmonary arterial hypertension animal was 
significantly upregulated compared to control, resulting in the excessive proliferation of 
PASMCs [45].  
 
     (3)  Store-operated Ca2+ entry 
 Depletion of Ca2+ in ER/SR triggers Ca2+ influx to replenish the Ca2+ stores and 
preserve the functions of ER/SR [46]. This mechanism of Ca2+ entry is called 
"capacitative Ca2+ entry" or "store-operated Ca2+ entry (SOCE)" [46,47]. Traditionally, it 
is known that SOCE is initiated typically by Ca2+ release through IP3 receptors (IP3Rs) 
activated by IP3 as the result of GPCR and RTK activation, resulting in store-operated 
inward current (ISOC) or Ca




sensors" in ER/SR is required for the coupling of Ca2+ depletion with SOCC in 
membrane. 
 There is strong evidence that SOCE is modulated by the ER/SR-resident Ca2+ 
sensor stromal interaction molecule (STIM) proteins, STIM1 and STIM2 isoforms, which 
have different Ca2+ sensitivity. STIM is a ER/SR membrane-spanning protein, composed 
of ER/SR lumen segment, containing Ca2+-sensitive EF hand near N-terminus, and 
cytoplasm segment containing ezrin/radixin/moesin (ERM) domains in C-terminus [49]. 
Particularly, STIM1 is expressed as a dimer stabilized by ERM domain in basal state, 
while the Ca2+ store depletion in ER/SR lumen, sensed by EF hand, causes the 
oligomerization of STIM1 molecules. The formation of STIM1 multimer results in the 
translocation of STIM1 and coveys the information of Ca2+ depletion to store-operated 
Ca2+ channels in cell membrane, mediated by complex domains in C-terminus [49,50]. 
Furthermore, studies also characterized that STIM2 has lower sensitivity to ER/SR 
[Ca2+]i than STIM1, and acts as another Ca
2+ sensor capable of detecting a small decrease 
in ER/SR [Ca2+]i, triggering SOCE [51]. 
 Over the past decade, many studies addressed that TRPC channels, such as 
TRPC1/4, are a crucial candidate for SOCE particularly in PASMCs [52,53]. Particularly, 
TRPC1-mediated SOCE is activated by the formation of a complex with STIM1 in 
PASMCs [54]. This typical Ca2+ current generated by TRPC1-STIM1 interaction is 
namely ISOC [55]. In addition, there is a novel aspect of SOCE mediated by the complex 
of STIM with Orai1, a pore subunit of Ca2+ release-activated Ca2+ channels (CRACs) in 
plasma membrane [55,56]. The mechanism has been shown that the complex of ERM 
domains in oligomerized STIM1 stimulate the dimerization of Orai1 dimers to form 
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tetrameric Orai1 channels, leading to generating inward Ca2+ current, called ICRAC [57]. 
Although Orai and TRPCs clearly function independently, evidence also elucidated that 
Orai-activating region of ERM domains in STIM1 has a capacity for binding to TRPC 
channels, suggesting the interaction between Orai1-STIM-TRPC for inward Ca2+ current 
[58]. Overall, those results implicate that functional activity of Orai1 and TRPC is 
regulated by STIM1 with both dependent and independent manner, contributing to 
generation of inward Ca2+ current for SOCE.  
 
     (4)  Other types of Ca2+ channels in plasma membrane 
 There are other types of Ca2+ permeable cation channels in cell membrane of 
PASMCs. Ligand-gated ion channels are transmembrane proteins which are activated by 
binding of specific ligands such as adenosine triphosphate (ATP) to P2X purinergic 
receptors [59], and urokinase plasminogen activator to N-methyl-d-aspartate receptor-1 
[60]. Another type of Ca2+ permeable channels called cyclic nucleotide-gated ion 
channels are also found in vascular smooth muscle [61,62,63]. They are activated by 
cyclic nucleotides such as cAMP and cGMP. However, their expression in PASMCs has 
not been clearly examined yet. 
 
   c. Ion channels that modulate Ca2+ entry 
     (1)  K+ channels 
 K+ channels are composed of pore-forming subunits (α-subunits) and accessory 
subunits (β-subunits) depending on their functional and structural diversity [64]. In 
PASMCs, there are at least three major groups of K+ channels characterized by several 
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biophysical and pharmacological properties: voltage-dependent K+ (KV) channels, Ca
2+-
activated K+ (KCa), and ATP-sensitive K
+ channels, contributing to changes in membrane 
potentials. [64,65,66,67]. It is clear that KV channels and KCa channels play important 
roles in modulating Ca2+ influx via voltage-gated Ca2+ channels in PASMCs [66]. 
 KV channels in PASMCs play an important role in regulating membrane resting 
potential [66]. The α subunits of the KV channels have six transmembrane domains and 
pore-formation regions and are encoded by the KV gene family, which comprises at least 
36 members grouped into 12 subfamilies (KV1–KV12) [68]. A reduction of KV channel 
activity causes membrane depolarization and the activation of VDCCs, leading to the 
elevation of [Ca2+]i in PASMCs and eventually pulmonary vasoconstriction. In contrast, 
activation of KV channels results in hyperpolarization and inhibition of Ca
2+ influx via 
VDCCs [66,69,70]. 
 KCa channels operate as a "negative feedback pathway" for the regulation of 
membrane potential and vasoconstriction [66,71]. KCa channels can be classified into 
three subtypes based on their biophysical properties: large-conductance and voltage-
dependent Ca2+-activated K+ (BKCa) channels, intermediate-conductance Ca
2+-activated 
K+ channels, and small-conductance Ca2+-activated K+ (SKCa) channels [72]. A rise in 
[Ca2+]i activates KCa channels, resulting in K
+ efflux, outward current, hyperpolarization, 
and deactivation of VDCCs [66,72]. It has been shown that local Ca2+-release events 
through ryanodine receptors (RyRs), called "Ca2+ sparks," evoke hyperpolarization and 
vasorelaxation in systemic vascular smooth muscles while Ca2+ sparks in PASMCs cause 
membrane depolarization vasoconstriction, implying that the coupling of RyR to KCa 




     (2)  Ca2+-activated Cl- channels 
 Ca2+-activated Cl- channels (CaCCs) are activated by [Ca2+]i at the range of 0.2–5 
µM, leading to an inward Cl- current in various cell types including PASMCs [74,75]. In 
general, elevated [Ca2+]i triggers activation of CaCCs, resulting in membrane 
depolarization and the subsequent activation of VDCCs to further increase depolarization 
and Ca2+ influx [74]. In particular, CaCC in PA smooth muscle is a major physiological 
target of Ca2+ sparks causing depolarization while other systemic vascular smooth muscle 
is associated with KCa channels leading to hyperpolarization [76]. Recent studies 
demonstrated that TMEM16A, a member of the TMEM16 family, is the main component 
of CaCC subunits in PASMCs [75,77,78]. Recently, Sun et al. demonstrated that 
prolonged hypoxia causes upregulation of TMEM16A and an increase in Cl- current 
through CaCCs in PASMCs [75], which is associated with elevated agonist-induced 
vasoreactivity in PA [79]. These results suggest that CaCCs play a potent role in Ca2+ 
homeostasis and physiological response in PASMCs  [75]. 
   
 2. Ca2+ release from intracellular Ca2+ stores in PASMCs 
 There are three major intracellular Ca2+ stores, namely the IP3R-gated and RyR-
gated Ca2+ stores in the ER/SR, and the nicotinic acid adenine dinucleotide phosphate 
(NAADP) receptor-gated stores in the endolysosomes [43,80,81,82]. Ca2+ release from 
these stores are triggered by specific Ca2+ second messengers, namely IP3, cyclic 
adenosine diphosphate-ribose (cADPR), and NAADP, respectively. These Ca2+-release 
channels may interact with each other through "cross-talk" mechanisms. In particular, 
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activation of Ca2+-release channels may result in depletion of Ca2+ stores in the ER/SR 
and may trigger SOCE. 
 
    a.  IP3R-gated Ca
2+ release 
  One of the most well characterized Ca2+ release mechanisms is IP3-dependent 
Ca2+ release. Ligand binding to GPCRs and RTKs activates PLC to convert 
phophatidylinositol 4, 5-bisphosphate (PIP2) to IP3 and DAG. IP3 activates IP3Rs on the 
ER/SR, resulting in Ca2+ release whereas DAG activates other pathways such as PKC 
signaling pathways resulting in diverse cellular activity [43,83]. Various types of agonists 
such as endothelin-1 (ET-1), angiotensin II (Ang II), acetylcholine, 5-HT, thromboxane, 
and growth factors stimulate the production of IP3 and activate to Ca
2+ release via the 
IP3R-gated channel in the ER/SR [83]. 
 There are three mammalian IP3R isoforms, IP3R1 to 3 [83,84,85]. IP3R1 is the 
major isoform in systemic vascular smooth muscle cells, and all three isoforms are 
expressed in PASMCs [73,86]. IP3Rs have many regulatory sites, which interact with 
Ca2+, ATP, and protein kinases, leading to modulation of channel function [87,88,89,90]. 
In particular, Ca2+ regulates the channel opening of IP3R in a biphasic manner, 
facilitating the channel opening at low Ca2+ (<300 nM) and inhibiting it at high Ca2+ 
(>300 nM), thereby leading to positive and negative feedback regulation of IP3R-gated 
Ca2+ release [89]. 
 In general, IP3R-gated Ca
2+ release is responsible for agonist-induced Ca2+ release 
and evokes "Ca2+ waves" and elevation of global [Ca2+]i, triggering vasoconstriction in 
vascular smooth muscle [73,91]. It has also been demonstrated that local Ca2+ events 
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from IP3Rs, called "Ca
2+ puffs," elicit spontaneous outward currents (STOCs) by 
activation of BKCa and SKca, leading to hyperpolarization and a decrease in Ca
2+ influx 
through VDCCs/VGCCs in smooth muscle cells [92]. Moreover, agonist-induced Ca2+ 
release through IP3R increases the occurrence of Ca
2+ sparks mediated by RyR-gated 
Ca2+ release, implying cross-talk between IP3R- and RyR-gated Ca
2+ release in PASMCs 
[73]. 
 
    b.  RyR-gated Ca2+ release 
 There are three different RyR subtypes; RyR1 was originally cloned from skeletal 
muscle, RyR2 was identified in cardiac muscle, and RyR3 was originally described in the 
brain. RyRs are tetrameric channels composed of four RyR monomers of each subtype 
and are distributed in many other tissues including vascular smooth muscles [82,93].  
RyR1 is activated mainly by a voltage-dependent mechanism with dihydropyridine 
receptors (i.e. L-type VDCCs) as the voltage sensor [94]. RyR2 and RyR3 are activated 
by Ca2+ entry or release through the Ca2+-induced Ca2+ release mechanism [4,95,96,97]. 
In addition, the activity of RyRs is regulated by many regulatory proteins and molecules 
including FK506 binding proteins (FKBPs), calmodulin, Ca2+-calmodulin-dependent 
kinase, PKA, triadin, junctin, and calsequestrin [82,88,98]. There is also clear evidence 
that the second messenger, cADPR, activates RyR2, leading to Ca2+ release in vascular 
myocytes including PASMCs [99,100,101]. The detailed mechanism and characteristics 
of cADPR are described in the section on cADPR and CD38. 
 RyR-gated Ca2+ release may operate as a frequency-dependent negative 
modulator of membrane potential [102,103]. There is clear evidence that RyR1 and RyR2 
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play important role in excitation-contraction coupling in skeletal (mechanical coupling) 
[104,105] and cardiac muscle (Ca2+-induced Ca2+ release), respectively [106]. In systemic 
vascular myocytes, RyR1 and RyR2 are required for the generation of Ca2+ sparks, and 
RyR3 is involved in the agonist-induced elevation of global [Ca2+]i [93,107,108]. Ca
2+ 
sparks are RyR-gated local Ca2+ release events. The elevation of these local Ca2+ signals 
in systemic myocytes leads to vasodilation and hyperpolarization via activation of KCa 
channels [102]. In contrast, Ca2+ sparks in distal PASMCs cause membrane 
depolarization [73,109,110]. In rat PASMCs, RyR2 is the most abundant of the three 
subtypes, and RyRs are differentially localized in the subsarcolemmal (RyR1/RyR2) and 
perinuclear regions (RyR3). Agonist-induced Ca2+ sparks in peripheral and perinuclear 
regions exhibit different spatiotemporal properties in PASMCs [93].  
 
    c.  NAADP-gated Ca2+ stores 
 Recent evidence indicates that Ca2+ stores are not limited to the ER/SR but are 
also present in other organelles such as endolysosomes [81,111,112]. In endolysosomes, 
vacuolar-type H+-ATPases generate H+ gradient across the organelle membrane. This 
gradient allows Ca2+ entry into endolysosomes via H+-Ca2+ exchangers [113]. Ca2+ 
release from the endolysosomal store is mediated by NAADP-sensitive channels 
[114,115,116]. NAADP is generated from inactive nicotinamide adenine dinucleotide 
phosphate (NADP) by the enzymatic activity of CD38 [116]. It was reported that 
NAADP-sensitive Ca2+ release channels on endolysosomes are encoded by two-pore 
channels (TPCs) [117]. Mainly, there are two subtypes of TPCs: TPC1 and TPC2. TPC1s 
are widely expressed in all stages of endolysosomes, and TPC2s are expressed 
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predominantly in late endosomes and lysosomes [118]. Western blot detected both TPC1 
and TPC2 in rat PA smooth muscle [114]. In particular, the mRNA level of TPC1 was 
approximately five times higher than that of TPC2 [114].  
 Functional studies in systemic vascular smooth muscle showed that NAADP-
gated Ca2+ release contributes to vasoconstriction induced by ET-1 and norepinephrine 
[119,120]. In PASMCs, NAADP triggers a Ca2+ burst (a spatially restricted Ca2+ release) 
and global Ca2+ waves, which are inhibited by depletion of endolysosomal Ca2+ stores 
and inhibition of RyRs, implying that NAADP-gated Ca2+ release is coupled to RyRs 
through Ca2+-induced Ca2+ release [114,121]. Moreover, integrin-specific ligands 
(GRGDSP) also trigger NAADP- and RyR-gated Ca2+ release in PASMCs [122]. These 
results suggest that cross talks between NAADP-gated and other Ca2+ release channels 
(e.g., RyR and IP3R) may play crucial roles in agonist-induced Ca
2+ signaling though 
complex interactions in PASMCs. 
 
II. CD38 as a master Ca2+ regulator 
 CD38 is a membrane glycoprotein discovered as a surface marker of lymphocytes 
[123,124]. It was subsequently reported that CD38 is a ubiquitous multifunctional 
ectoenzyme responsible for the synthesis of the second messengers cADPR and NAADP 
[125,126]. In this section, the multifunctionality of CD38 and its products cADPR and 
NAADP is reviewed. The crystal structure of cADPR and NAADP is shown in Figure 1.2 
[115]. 
 
   A. Generation of cADPR and NAADP by CD38 
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  In 1987, Lee et al. showed that a metabolite of nicotinamide adenine dinucleotide  
(NAD+) in sea urchin egg increases Ca2+ release from the intracellular Ca2+ store with a 
potency comparable to IP3 [127,128]. They subsequently identified that the metabolite is 
cADPR [129,130,131], which is the endogenous messenger for the activation of RyR-
gated Ca2+ stores [132,133]. cADPR exerts its action by binding to FKBP12/12.6, an 
accessory protein that stabilizes RyR1/3 and RyR2, respectively, causing its dissociation 
from RyRs to initiate Ca2+ release [134,135]. Furthermore, cADPR may increase the 
 
Figure 1.2. Cristal structure of cADPR and NAADP    Left: The C8 of cADPR is 
indicated by a white asterisk. Attachment of a bromo (8-bromo-cADPR) or an amino 
(8-NH2-cADPR) group at this position converts the compound to a specific 
antagonist of cADPR. Right:  The structure of NAADP is identical to that of its parent 
NADP, except that the amide nitrogen of the nicotinamide group of NADP is changed 
to oxygen as indicated by the circle. Blue, nitrogen; red, oxygen; yellow, phosphorus; 




activity of SERCA in removing cytosol Ca2+ and refilling the ER/SR [136]. These studies 
clearly suggested that cADPR is an important regulator of intracellular Ca2+ stores and 
release. 
 The enzyme that catalyzes the formation of cADPR from NAD+ was first 
identified in Aplysia Californica and is known as ADP-ribosyl cyclase [137]. Subsequent 
studies found that 86 of the 285 amino acids in ADP-ribosyl cyclase from Aplysia 
Californica are identical to the human lymphocyte surface antigen CD38, which is an 
approximately 45 kDa transmembrane type II glycoprotein ubiquitously distributed in 
mammalian tissues [138,139,140,141,142,143,144]. CD38 was first identified as a T and 
B lymphocyte-specific surface antigen and is expressed at the late stage of maturation 
[123,145]. Subsequently, it was reported that CD38 also converts NAD+ and cADPR to 
ADP-ribose (ADPR), indicating that it is a multifunctional enzyme that uses more than 
one substrate [146,147,148]. The multifunctionality of CD38 is dependent on pH. A 
neutral pH favors cylcase activity for converting NAD+ to cADPR [149]. Under an acidic 
environment, CD38 catalyzes a base-exchange reaction for β-NADP+ and nicotinic acid 
to generate NAADP [149,150].  
As mentioned above, NAADP is a highly potent Ca2+-mobilizing agent, which 
triggers Ca2+ release from thapsigargin-insensitive lysosome-related acidic organelles that 
are fundamentally different from the IP3- or cADPR-dependent stores [112,150,151]. In 
addition, CD38 also hydrolyzes NAADP to ADP-ribose-2’-phosphate (ADPRP) at an 
acidic pH [144]. The pH dependency of CD38 is dictated by Glu-146 and Asp-155 in the 
active site of CD38. Under neutral pH, these "acidic residues" are negatively charged and 
repel the negatively charged nicotinic acid, leading to the selection of substrate and its 
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consequent metabolite [152]. A schematic overview of CD38 enzyme activity is shown in 
Figure 1.3 [126]. 
 Moreover, CD38 is a key enzyme for NAD+ degradation in mammalian cells 
[125]. Research provided strong evidence that nicotinamide phosphoriboxyltransferase 
(NAMPT; the same with visfatin or PBDF) plays a key role in de novo synthesis of 
NAD+ [153,154]. However, little is known about the degradation of cellular NAD+ levels 
 
 
Figure 1.3. Schematic diagram of multifunctionality of CD38   The 
multifunctionality of CD38 activity is dependent on circumstant pH; enhanced 
cyclase activity in neutral pH and catalase activity in acidic pH. The product of 
cyclase and catalase (cADPR and NAADP, respectively) is also hydrolyzed into 
ADPR and ADPPR, respectively, by CD38. Abbreviations used: cyclic ADP-ribose, 
cADPR; ADP-ribose, ADPR; nicotinic acid adenine dinucleotide phosphate, 
NAADP; nicotinic acid, NA; ADP-ribose-2’-phosphate, ADPRP. This image is cited 




except regarding CD38 as a glycohydrolase [155]. The catalytic site of CD38 is located 
on the extracellular domain of the cell; yet the topological model for determining cADPR 
internalization is still unclear [156]. A recent study provided evidence that CD38 can be a 
type II or type III protein. In the latter case, the enzyme-catalytic domain is oriented 
toward the cytoplasm such that it is more efficient in generating intracellular cADPR than 
type II CD38. These results strongly suggest that flipping the catalytic sites of CD38 is an 
important regulatory mechanism for mediating Ca2+ release [157]. A schematic overview 
of CD38-dependent Ca2+ release mechanism is shown in Figure 1.4 
 
   B. CD38 and TRPM2 
 CD38 may modulate other channels in addition to RyR- and NAADP-gated Ca2+ 
stores, such as TRPM2 [158]. TRPM, which is named after the tumor suppressor 
melastatin, has eight mammalian subtypes, TRPM1 to 8, and plays an important role in 
Ca2+ mobilization in different cell types [159,160]. TRPM2, previously called LTRPC2, 
is known as a "chanzyme" (channel enzyme) due to the presence of an enzymatic domain 
in its C terminus [158]. The C terminus of TRPM2 has a regulatory binding motif (a 
Nudix-like domain) that is targeted by ADPR [160,161]. Since CD38 generates ADPR 
through hydrolysis of NAD+ and cADPR at neutral pH, TRPM2-gated Ca2+ mobilization 
is influenced by the enzyme activity of CD38. TRPM2 is expressed in the plasma 
membrane, contributing to Ca2+ influx, but is also found in the lysosomal membrane, 
implying that it may operate as a Ca2+ release channel [161].  
 ADPR triggers the activation of TRPM2, contributing to the elevation of [Ca2+]i  
in various cell types such as pancreas β cells (release) [161], immunocytes (influx) 
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[162,163], and insulinoma cell lines (influx) [164]. In vasculature, TRPM2 plays a 
pivotal role in cell death depending on oxidative and nitrosative stress, as well as 
interaction with silent information regulator 2 [159]. Nonetheless, this information 
suggests that CD38 contributes to diverse cell physiology through the generation of 
different second messengers for Ca2+ mobilization in PASMCs. However, to date, the 
term for the activation of CD38 generally refers to the enhancement of cyclase and 
 
Figure 1.4. Schematic diagram of CD38-dependent Ca2+ release   CD38 
synthesizes two messenger molecules, cADPR and NAADP,  which activate RyR in 
ER/SR and the NAADP-dependent Ca2+ channel two-pore channel (TPC) in 




catalase activity in synthesizing cADPR and NAADP, respectively, rather than of the 
hydrolase activity for the generation of ADPR. 
 
   C. Physiological function of CD38 
 Because CD38 was first discovered as a surface marker for lymphocyte 
differentiation, the investigation was initially focused on its physiological function as an 
antigen for proliferation to apoptosis of T and B cells, as well as hematopoietic cells 
[123,165,166]. However, it is now clearly established that the enzymatic activity of CD38 
plays an important physiologic function along with NAD+ consumption and 
cADPR/NAADP synthesis, contributing to intracellular Ca2+ mobilization in a variety of 
cells such as cardiomyocytes [167,168], neuronal cells [169,170], osteoblasts [171], 
hepatic stallate cells [172], pancreatic acinar and β cells [173,174], airway smooth muscle 
cells [141,175], renal arterial smooth muscle cells [120], and PASMCs [176,177]. 
 CD38 knockout (KO) mice exhibit phenotypic defects including depressed insulin 
secretion due to impairment in pancreas acinar and β cells [173,178] and increased 
susceptibility to bacterial infection due to disruption in the chemotaxis of neutrophils 
[179]. In addition, recent population studies provided evidence that the functional defect 
of CD38 is correlated with HIV infection, leukemia, myeloma, solid tumors, type II 
diabetes mellitus, asthma, bone metabolism, and autism spectrum disorder 
[180,181,182,183,184]. However, while the cADPR level decreases in many tissues in 
CD38 KO mice, the levels in the heart and brain are not significantly different than those 
of the wild type. This implies that other types of ADP-ribosyl cyclase, in addition to 




   D. Regulation of CD38 in vascular smooth muscle 
CD38 is widely distributed in many different types of vascular smooth muscle. Its 
expression has been reported in the aorta, coronary artery, and PA [122,186,187,188]. 
Furthermore, studies also have found ADP-ribosyl cyclase activity in the aorta, coronary 
artery, renal artery, and PA. Direct application of cADPR to vascular microsomes causes 
intracellular Ca2+ release [186,187,189,190,191]. Activation of the cyclase has been 
implicated in vascular responses induced by norepinephrine, ET-1, Ang II, agonists of 
M1-muscurinic receptors, and reactive oxygen species [192,193,194,195,196]. A study 
demonstrated that Ang II and NE-induced  elevation of [Ca2+]i in renal afferent arterioles 
in vitro and renal vasoconstriction in vivo were attenuated by more than 50% through 
pharmacological inhibition of CD38 or RyRs [197].  Moreover, vascular response to 
agonists including Ang II, NE, and ET-1 decreased in the aorta and renal artery of CD38 
KO mice [186,197].  
Similar to cADPR, application of NAADP promotes vascular smooth muscle 
micosomal Ca2+ release [198,199]. ET-1 and NE also stimulate production of NAADP in 
coronary arterial myocytes and renal afferent arterioles triggering Ca2+ mobilization from 
the lysosomal Ca2+ store [119,120]. In addition, a study using CD38 KO mice showed 
that activation of the death receptor Fas stimulated lysosome-dependent Ca2+ release 
though NAADP [111]. 
 
   E. Regulation of CD38 in PASMCs 
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 Expression of CD38 and the activity of ADP-ribosyl cyclase have been reported 
in PASMCs [122,191]. However, there is little information on the regulatory mechanism 
of CD38 including agonist-induced Ca2+ mobilization mediated by CD38 activation in 
PASMCs. A study examining ET-1-induced elevation of Ca2+ sparks and Ca2+ bursts 
mediated by RyR- and NAADP-gated Ca2+ release, respectively, showed that ET-1 
activates the cyclase and catalase activity of CD38 [114]. It was also reported that the 
specific integrin-ligand GRGDSP stimulates the production of cADPR in PASMCs and 
activates RyR- and NAADP-gate Ca2+ release [122]. Indeed, NAADP induces spatially 
restricted Ca2+ bursts, which initiates global Ca2+ waves [121,200]. It was postulated that 
the lysosome-related Ca2+ stores and RyR-gated Ca2+ stores are co-localized to form a 
highly specialized "trigger zone" for NAADP-dependent Ca2+ signaling such that the 
NAADP-induced Ca2+ signal is amplified by RyRs.  
 One of the unique features of Ca2+ mobilization in PASMCs is hypoxia-induced 
Ca2+ response mediated by RyR-gated Ca2+ release, contributing to hypoxic pulmonary 
vasoconstriction in response to acute hypoxic exposure [201,202,203]. To date, there are 
at least two hypotheses for the mechanism of hypoxia-induced activation of RyRs, which 
are related to cADPR and reactive oxygen species (ROSs), respectively. One of the 
hypotheses proposed that the reduction in the ratio of β-NAD+ to β-NADP+ by hypoxia 
stimulates the activation of RyRs, leading to an increase in [Ca2+]i. Increased β-NADP
+ 
inhibits hydrolase activity of CD38, contributing to accumulation of cADPR, which 
triggers RyR-gated Ca2+ release from SR [176]. This hypothesis suggests that CD38 
plays an important role for redox sensing in PASMCs under acute exposure to hypoxia. 
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However, the information has been limited to acute hypoxia, and the possible alteration 
of CD38 under prolonged exposure to hypoxia in PASMC is completely unknown. 
 Indeed, the regulatory mechanism of CD38 and CD38-dependent Ca2+ release 
mechanism as well as CD38-mediated physiologic response in PASMC are very scanty. 
Because of the lack of information, this thesis research focused on the regulatory 












BACKGROUND AND INTRODUCTION: 
PULMONARY HYPERTENSION AND ALTERATION OF 
CALCIUM REGULATION   
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 Chapter 1 reviewed the physiology and the regulatory mechanism of intracellular 
Ca2+ with emphasis on pulmonary arterial smooth muscle cell (PASMC). In this chapter, 
it is followed by a overview on pulmonary hypertension (PH) and its association with the 
alteration of Ca2+ homeostasis in PASMC. Review on this chapter further focuses on a 
novel mechanism of intracellular Ca2+ release mediated by the CD38-dependent Ca2+ 
pathways, which may contribute to the regulation and dysregulation of Ca2+ homeostasis 
in PASMC particularly under chronic hypoxic (CH) exposure that may cause chronic 
hypoxia-induced pulmonary hypertension (CHPH). 
 
I. Pulmonary hypertension 
   A. Overview of pulmonary hypertension 
 PH in humans is defined as a mean pulmonary arterial pressure (PAP) higher than 
25 mm Hg at rest or 30 mm Hg during physical activity as well as increased pulmonary 
vascular resistance higher than 240 dynes/sec/cm-5 [204]. According to the recently 
updated clinical classification of PH by the Fourth World Symposium in Dana Point 2008, 
PH is categorized into five groups: (a) pulmonary arterial hypertension, (b) PH with left 
heart disease, (c) PH associated with lung disease and/or hypoxemia, (d) PH due to 
chronic thrombotic and/or embolic disease (CTEPH), and (e) PH due to miscellaneous 
factors [205,206,207]. PH is associated with multiple risk factors including gender, family 
history, disease, toxins, behavior patterns, and environment [205]. Although the 
mechanism varies depending on the type of PH, the elevation of PAP is clearly associated 
with increased pulmonary vascular resistance due to the alteration of structure and 
contractility in vasculature, eventually leading to right heart failure [208]. In particular, 
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exposure to chronic hypoxia due to high altitude or airway/alveolar disease such as 
chronic obstructive pulmonary disease and fibrosis causes CHPH [206]. This dissertation 
focuses on CHPH in order to understand the possible mechanism linked to the underlying 
Ca2+ mechanism in PASMCs. 
Table 2.1. Revised WHO classification of PH (reprinted from ACCF/AHA 2009 




   B. Hypoxia-induced pulmonary hypertension  
 As described above, acute exposure to hypoxia causes hypoxic pulmonary 
vasoconstriction (HPV) in PA [202]. HPV is a unique feature in PAs that shunts the 
blood to the O2-rich regions of the lungs to match the ventilation-perfusion ratio 
[176,209,210]. However, prolonged exposure to hypoxia causes PH, which is 
characterized by increased vasomotor tone; enhanced  vasoreactivity to agonists 
including ET-1, Ang II, and serotonin (5-HT); and remodeling of pulmonary vasculature 
[75,211,212,213], eventually leading to right heart failure and worsening the prognosis of 
the underlying disease [207].  
 The pathogenesis of CHPH involves multiple factors with a wide spectrum of 
mechanisms in PASMCs. Heterozygous mice of hypoxia-inducible factor-1 (HIF-1), an 
O2-sensitive transcription factor, demonstrated a delayed development of CHPH [214]. 
Inhibition of the translocation of nuclear factor of activated T-cells (NFAT) activated by 
Ca2+-calcineurin attenuates CHPH and decreases [Ca2+]i proliferation in PASMCs 
[215,216,217]. Abnormal regulation of endothelium-derived factors, including enhanced 
ET-1 and reduced nitric oxide production, also contribute to the development of CHPH 
[218,219].  Moreover, the vasoactive agonists that activate Rho A/Rho kinase signaling—
such as ET-1, thromboxane A2, norepinephrine, histamine, and serotonin (5-HT)—all 
contribute to development of CHPH [220,221,222,223,224,225]. Accordingly, elevation 
of Rho kinase activity alters cytoskeleton properties including increased stress fiber 
formation [226] and myofilament Ca2+ sensitivity in PASMCs [227]. Excessive ROS 
generation mediated by NADPH oxidase [228,229] and xanthine oxidase [230,231] are 
also involved in the development of CHPH. Furthermore, alterations of extracellular 
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matrix deposition and production, including collagen production and enhanced serine 
elastase activity, are associated with the development of CHPH [232,233].  
 
II. Alteration of Ca2+ homeostasis in PASMCs 
 Substantial evidence indicates that CH causes intrinsic changes in ionic balance 
and Ca2+ homeostasis in PASMCs, leading to membrane depolarization, elevation of 
resting [Ca2+]i, and changes in electrophysiological and Ca
2+ responses to 
vasoconstrictors and vasodilators [234,235,236,237,238]. These functional changes in 
PASMCs involve alterations in multiple Ca2+ pathways and are crucial for the 
development of CHPH [69,239]. An increase in [Ca2+]i stimulates gene transcription 
through activation of Ca2+-regulated transcription factors such as NFAT, a process known 
as excitation-transcription coupling, which is essential for vascular remodeling and 
smooth muscle proliferation [240,241]. Elevated [Ca2+]i also promotes Ca
2+ binding to 
calmodulin and activates Ca2+-calmodulin-dependent myosin light chain kinase and 
actin-myosin interactions to enhance vasoconstriction. As mentioned, enhanced agonist-
induced Ca2+ influx [242] and enhanced myofilament Ca2+ sensitivity depending on Rho 
kinase pathways operate synergistically to promote vasoconstriction [227]. 
 
   A. Hypoxic-induced alteration of Ca2+ influx  
 1. K+ channel dependence 
 CH alters Ca2+ influx through multiple mechanisms in PASMCs. It has been 
clearly demonstrated that hypoxia suppresses K+ currents [69]. The activity of KV 
channels (KV1.5 and KV2.1) in PASMCs significantly decreases under CH exposure and is 
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associated with the downregulation of KV channel expression 
[70,234,235,236,237,243,244,245,246,247]. Since the KV channel is the major 
conductance controlling the resting membrane potential [70,238,248], the downregulation 
of KV channels causes membrane depolarization and subsequent activation of the VDCCs, 
leading to Ca2+ influx and increase in [Ca2+]i [234,249]. It is interesting to note that the 
heterogeneity of KV channel expression in proximal and distal PA may lead to differential 
responses to CH in terms of vascular remodeling, cell proliferation, and apoptosis [250] 
 It is unclear, however, which other types of K+ channels are involved in the 
response to CH in PASMC. Large-conductance KCa (BKCa) channels, which are inactive 
at resting membrane potential, apparently do not play a primary role in the development 
of CHPH [251,252,253]. The general consensus on the role of BKCa is that the elevation 
of [Ca2+]i activates BKCa, limiting the extent of depolarization as a form of regulatory 
feedback to VDCC-gated Ca2+ entry in PASMCs. Likewise, although it was reported that 
a fall in ATP during hypoxia triggers ATP-sensitive K+ channels, which are regulated by 
the ADP/ATP ratio, the activity was not directly required for the alteration of K+ entry 
[254]. The activity of the channels is dependent on ATP content, which decreases during 
hypoxic exposure. ATP-sensitive K+ channels may be involved in the vasorelaxation 
phase of HPV [251,254]. Nielsen et al. showed that the expression of polyunsaturated 
fatty acid-activated two-pore domain K+ channel (K2P) is altered in hypoxia, contributing 
to endothelium hyperpolarization and pulmonary artery relaxation in hypoxic PH [255].  
 
 2. TRP channels 
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 CH can also modulate Ca2+ influx through non-voltage-dependent and 
nonselective cation channels such as TRP channels, which are known to have diverse 
physiological functions in vascular smooth muscles [21,256]. In particular, previous 
studies demonstrated that CH upregulates the store-operated TRPC1 and receptor-
operated TRPC6 expression in PAs and enhances both SOCE and ROCE in PASMCs 
[238]. Differential inhibition of those two pathways using a pharmacological blocker 
indicated that the SOCE is responsible for elevated resting [Ca2+]i in PASMCs and resting 
vasotone in PAs from CH animals. A subsequent study also demonstrated that the 
upregulation of TRPC1 and TRPC6 is the direct effect of hypoxia on PASMCs and 
requires the full expression HIF-1α [257]. Sildenafil, a specific phosphodiesterase-5 
inhibitor, which is known to attenuate CHPH [258], significantly reduces basal [Ca2+]i 
and SOCEs mediated by decreased expression of TRPC1 an TRPC6 [259,260,261]. Also, 
sodium tanshinone IIA sulfonate inhibited the CH-induced upregulation of TRPC1/6 in 
PASMCs, contributing to attenuating basal [Ca2+]i and cell proliferation [262].  
 In particular, recent studies also provided evidence that TRPC1 and TRPC6 
differentially contribute to the full development of CHPH. The regulatory mechanism of 
HPV by acute exposure to hypoxia was absent in TRPC6 KO mice while TRPC6 KO 
mice were not protected from CHPH, including vascular remodeling and right heart 
hypertrophy [263]. In contrast, TRPC1 KO mice was failed to experience pulmonary 
vascular remodeling underlying the development of CHPH [264]. In particular, CH-
induced enhancement of the vasomotor tone of PA was blunted in TRPC1 KO mice but 
not in TRPC6 KO mice CHPH, whereas CH-induced augmentation of vasoreactivity to 
5-HT decreased in both TRPC1 and TRPC6 KO mice PAs [38]. These results strongly 
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indicate that TRPC1 and TRPC6 in PA differentially contribute to the development of 
CHPH with discrete, time-dependent roles when exposed to hypoxia. 
 In the monocrotaline (MCT)-induced pulmonary arterial hypertension model 
(MCT causes pulmonary endothelial damage and PA remodeling) results in increased 
SOCE mediated by the upregulation of TRPC1 and TRPC4, leading to the enhancement 
of vasoreactivity to ET-1 in PASMCs [265]. Further studies demonstrated that the 
absence and inactivation of TRPC4 attenuated the severity of lesion formation in PA and 
right heart failure, indicating that TRPC4 is critically associated with the development of 
pulmonary arterial hypertension [265,266].  
 An increasing number of studies have also implicated the roles of other TRP 
channels in CHPH development. A recent study demonstrated that TRPV, a mechano-
sensitive vanilloid TRP channel, is the only CH-induced upregulated channel among the 
members of the TRPV and TRPM subfamilies. Since pharmacological activation of 
TRPV1 and TRPV4 can trigger an increase in the migration of PASMCs, its upregulation 
may contribute to PH development [39,267]. In particular, the development of CHPH 
was significantly attenuated in TRPV4 KO mice [37,39]. TRPV4 gene deletion also 
decrease 5-HT-induced [Ca2+]i and reduce vasoreactivity to 5-HT compared to the wild 
type under CH exposure [37,39].  
It was also reported that a TRPV4-mediated increase in [Ca2+]i was significantly 
attenuated by the inhibition of RyR2, and both TRPV4 and RyR2 expression are 
enhanced in CH rats. This suggests complex interplay between TRPV4 and RyR2 may 
also contribute to the development of CHPH [268]. Moreover, the expression of TRPM8 
is significantly declined in the PAs of both CHPH and MCT-induced PH. It is associated 
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with decreased TRPM8 menthol-induced vasorelaxation in PH rats, indicating that the 
downregulation of TRPM8 may associate with increased vasoreactivity in PH  [269]. 
 
 3. Ca2+ channels 
 It is unequivocal that VDCC-gated Ca2+ influx increases with membrane 
depolarization mediated by K+ channels in PASMCs during CHPH [270,271]. 
Pharmacological inhibition of L-type Ca2+ channels (Cav1.2), such as nifedipine or 
verpamil, partially attenuated CHPH [35,272,273,274,275], implying that the activity of 
Cav1.2 may be enhanced in PAs under CH exposure [35,276]. In addition, evidence also 
demonstrates that the expression of VDCCs in PASMCs is upregulated in response to CH.  
Wan et al. demonstrated that both Cav1.2 (L-type) and Cav3.2 (T-type) are specifically 
upregulated in PA but not in systemic vasculature under CH exposure, suggesting that 
upregulation of both L- and T-type VDCCs may play a role in CHPH development [35]. 
 However, it was reported that an ET-1-induced change in [Ca2+]i in PASMCs is 
altered and mediated by VDCC independent from the alteration of membrane potential 
after CH exposure. Meanwhile, ET-1 neither triggers Ca2+ release nor alters membrane 
potential mediated by the inhibition of K+ channels following CH exposure [236,274]. 
Subsequent studies demonstrated that ET-1 initiates a Ca2+ influx through VDCCs in 
PASMCs from CH rats, mediated by activation of PKC, Rho kinase, and tyrosine kinases 
[277]. 
 
 4. Other channels  
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 The Ca2+-dependent channels of PASMCs are also affected in CHPH. Although 
KCa channels may not contribute to the process of CHPH development, Sun et al. recently 
demonstrated that CH enhances the activity of CaCCs in PASMCs through upregulation 
of TMEM16A, a member of the TMEM16 family, contributing to increased agonist-
induced pulmonary vasoconstriction via the activation of VDCC-gated Ca2+ influx [75]. 
In addition, the acid-sensing ion channel 1 (ASIC1), another novel channel, may 
modulate other mechanisms of Ca2+ entry, contributing to CHPH. In particular, Jernigan 
et al. showed that ASIC1 may contribute to SOCE in pulmonary vascular smooth muscle 
[278]. A subsequent study also demonstrated that elevation of SOCE in PA from CH rats 
was prevented by the inhibition of ASIC1, leading to the speculation that the CH-induced 
enhancement of SOCE is mediated in part by ASIC1 in PASMCs and contributes to the 
development of CHPH [279,280]. 
   
   B. Hypoxic-induced alteration of intracellular Ca2+ release 
 Despite the well-established investigation of the extracellular Ca2+ influx, the 
information on the alteration of intracellular Ca2+ release mechanisms in PASMCs during 
CH is scant. Bonnet et al. found that in the early stage (1–2 weeks) of CH, the main PA 
rings in rats exhibited spontaneous and rhythmic contractions, spike-like membrane 
depolarization, and elevation in resting [Ca2+]i. The spontaneous rhythmic contraction 
was inhibited by disabling Ca2+ release from SR using ryanodine, tetracaine, or CPA 
[281]. This spontaneous rhythmic contraction of the main PA diminished after 3–4 weeks 
of CH when vascular remodeling and PH was fully established, suggesting that there is a 
time-dependent alteration of the Ca2+ release mechanism from SR stores under CH. 
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 Increasing evidence indicates that CH increases the level of intracellular ROS 
originating from mitochondria and NADPH oxidase in PASMCs [282,283]. Accordingly, 
the elevation of ROS is responsible for hypoxic-induced elevation of [Ca2+]i mediated by 
Ca2+ release [284]. In particular, the CH-induced generation of ROS triggers dissociation 
of the complex of RyR2 and FK506 binding protein 12.6 (FKBP12.6) [285]. As 
mentioned above, FKBP12.6 dissociation can be regulated by cADPR [286]. Yet, the 
regulation of cADPR synthesis in PASMCs by CH has not been established. Moreover, 
exogenous application of ROS also activates Ca2+ release via both IP3R- and RyR-gated 
Ca2+ stores in PASMCs [287]. These results imply that CH may enhance generation of 
ROS, triggering the activation of RyR- and IP3R-gated Ca
2+ release in PASMCs. 
  
   C. Regulation of CD38 by hypoxia in PASMCs 
 Recent studies demonstrated that CD38 appears to play an important role in acute 
HPV. The hypoxic response in PAs or PASMCs has been shown to be consistently 
suppressed by the inhibition of RyRs [177,191,201,288,289]. Studies of rabbit and rat 
PAs showed that acute exposure to hypoxia promotes the accumulation of cADPR to 
elicit Ca2+ release from RyR-gated Ca2+ stores to initiate vasoconstriction in PAs 
[177,191]. Particularly, Wilson et al. demonstrated that (a) acute hypoxia reduces the 
ratio of β-NAD+ to β-NADH+ in PA, (b) β-NADH+ inhibits the hydrolase activity of 
CD38, and (c) accumulation of cADPR leads to HPV mediated by RyR-gated Ca2+ 
release. Based on these observations, acute hypoxia may have a direct influence on 
CD38-dependent mechanisms, and CD38 may act as a redox sensor in PASMCs [191]. 
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 Nevertheless, although there is still controversy about the role of CD38 as a redox 
sensor in HPV [290], there is no systematic research on the role of CD38 in the 
regulation of intracellular Ca2+ mobilization, in particular Ca2+ release, in PASMCs. 
Furthermore, it is completely unknown whether CH regulates the expression and activity 
of CD38, as well as cADPR and NAADP-dependent Ca2+ release, in PASMCs.  
 
III. Statement of thesis objective 
 Ca2+ is an indispensible element that plays a pivotal role in maintaining normal 
cell function. The regulatory mechanism of intracellular Ca2+ is a complex response to 
chemical and physical stimulus in PASMCs. Profound changes in [Ca2+]i homeostasis 
occur due to CH, but the mechanisms for these changes are still not fully understood. In 
particular, the functional alterations in intracellular Ca2+ release processes in PASMCs 
have been barely investigated. Thus, the overall aim of this thesis research is to 
investigate the novel mechanism of CD38-dependent Ca2+ release and the changes in its 
enzymatic activity and expression in PASMCs under exposure to CH.  
 To investigate the objectives, the first aim of this dissertation is to determine the 
underlying mechanism of agonist-induced CD38 activation using Ang II as the activator 
of intracellular Ca2+ release in PASMCs. The second aim is to investigate the CH-
induced alterations of CD38-dependent Ca2+ pathways in PASMCs to elucidate their 
contributions in the pathophysiology of CHPH.   
 This research successfully reveals the novel roles of CD38-dependent Ca2+ 
pathways in the physiological regulation of pulmonary vascular reactivity and the 
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pathophysiology of CH-induced PH. Proof of these concepts may lead to the discovery of 









CD38 MEDIATES ANGIOTENSIN II-INDUCED INTRACELLUAR CALCIUM 




 CD38 is a multifunctional enzyme that synthesizes the endogenous Ca2+ 
mobilizing messengers cADPR and NAADP. cADPR and NAADP activate ryanodine 
receptors (RyRs) of the endoplasmic/sarcoplasmic reticulum (ER/SR) and NAADP-
sensitive endolysosomal Ca2+ stores, respectively; further, they are thought to play 
important roles in the regulation of [Ca2+]i and vascular functions.  However, information 
on the physiologic functions and the regulatory mechanisms of CD38 in PASMCs is 
scanty. This study characterized the expression of CD38, and its roles in angiotension II 
(Ang II)-induced vasoconstriction in PAs and Ang II-induced Ca2+ release (AICR) in 
PASMCs. Examination of the expression profile of CD38 in various rat arteries found a 
relatively high level of CD38 expression in PA-smooth muscle. Application of Ang II to 
PASMCs elicited Ca2+ response composed of both extracellular Ca2+ influx and 
intracellular Ca2+ release AICR activated in the absence of extracellular Ca2+ was 
significantly reduced by pharmacological or by siRNA inhibition of CD38, implying that 
CD38 mediates AICR in PASMCs.  AICR was suppressed by the cADPR antagonist 
cADPR 8-Br-cADPR or the inhibition of the RyR-gated Ca2+ released with ryanodine.  It 
was also suppressed by the NAADP-antagonist Ned-19 or the disruption of 
endolysosomal Ca2+ stores by the vacuolar H+-ATPase inhibitor bafilomycin A1. 
Suppression of AICR by the inhibition of cADPR- and NAADP-dependent pathways was 
non-additive, indicating inter-dependence between RyR- and NAADP-gated Ca2+ release 
in PASMCs. Furthermore, AICR was inhibited by the PKC inhibitor staurosporine, the 
non-specific NADPH oxidase (NOX) inhibitor apocynin and DPI, the NOX2 specific 
inhibitor gp91ds-tat, and the ROS scavenger TEMPOL. These results, for the first time, 
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provide evidence that Ang II activates CD38-dependent Ca2+ release via the PKC-NOX2-
ROS pathway in PASMCs.  
 
Introduction 
 CD38 is a 45 kDa trans-membrane glycoprotein ubiquitously distributed in 
mammalian tissues, including inflammatory cells, brain tissue, pancreas, cardiac muscles, 
and airway and vascular smooth muscle cells [126,137,291]. CD38 is a multifunctional 
enzyme that serves as an ADP-ribosyl cyclase, synthesizes cyclic ADP-ribose (cADPR) 
from β-NAD+, and acts as a catalase, producing nicotinic acid adenosine diphosphate 
(NAADP) from β-NADP+ through a base-exchange reaction [148,149,152]. Additionally, 
both products, cADPR and NAADP, can be hydrolyzed by CD38 to form ADP-ribose 
and ADP-ribose phosphate, respectively [152,292,293]. cADPR is the endogenous ligand 
of RyRs [132,133]. It binds to the FK506 binding protein, an accessory protein that 
stabilizes RyRs on endoplasmic/sarcoplasmic reticulum (ER/SR), causing its dissociation 
from RyRs to initiate channel activation [134,135]. NAADP is the most potent Ca2+ 
mobilizing messenger to date, which triggers Ca2+ release from endolysosomes [150,151]. 
Recent studies identified the two-pore channels (TPC1 and TPC2) as the NAADP-
activated Ca2+-release channels [117,294,295]. It has been suggested that NAADP either 
binds directly to TPCs or to an accessory protein of the TPC complex to activate 
endo/lysosomal Ca2+ release [296].  
To date, CD38 expression has been reported in various types of systemic arteries 
[186,187,188,196]. Endogenous vasoconstrictors such as norepinephrine (NE), 
endothelin-1 (ET-1), and angiotensin II (Ang II) can activate the cyclase and catalase 
activities of CD38, contributing to the elevation of [Ca2+]i and vasoconstriction in 
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systemic arteries [120,168,193,297,298].  These agonists of mediated by G-protein 
coupled receptor (GPCR) signaling pathways activate phospholipase C (PLC) to 
synthesize inositol trisphosphate (IP3) and diacyglycerol (DAG) from 
phosphatidylinositol bisphosphate. IP3 activates the IP3 receptor, which releases 
intracellular Ca2+ from SR in vascular smooth muscle cells (VSMCs) [299,300]. 
Evidence also demonstrated that Ang II can activate NAD(P)H oxidases (NOXs), in 
particular NOX2, to increase the production of reactive oxygen species (ROS) in VSMCs 
[301,302,303,304,305,306]. Ang II facilitates the assembly of NOX2 subunits by the 
phosphorylation of p47phox, leading to the coupling of p47phox and gp91phox, and ROS 
generation [307]. Moreover, previous studies showed that ROS production is associated 
CD38 activation [194,308,309,310], and that Ang II stimulates NOX to generate ROS, 
leading to enhanced ADP-ribosyl cyclase activity in afferent arterioles [305].  
 CD38 expression and its cyclase and hydrolase activity have been reported in rat 
pulmonary arteries (PA) and pulmonary arterial smooth muscle cells (PASMCs) 
[122,176,191].  ET-1 has also been shown to elicit Ca2+ responses in PASMCs, partially 
through NAADP-gated Ca2+ release and cross-activation of RyRs by Ca2+-induced Ca2+ 
release [114,121]. Moreover, integrin-ligand GRGDSP increases the production of 
cADPR and activates Ca2+ release from both the RyR-gated Ca2+ stores and the 
endolysosomal Ca2+ store [122]. However, the mechanism underlying agonist-induced 
activation of CD38 in PASMCs is still unclear. In this study, we compared the expression 
of CD38 in pulmonary and systemic arteries, determined the contribution of CD38 in 
Ang II-induced Ca2+ release (AICR), and examined the signaling mechanism of Ang II-
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induced activation of CD38 in PASMCs. We found that Ang II activates CD38 dependent 
Ca2+ release via the PKC-NOX2-ROS pathway in PASMCs. 
 
Method 
Preparation of rat PA tissue and PASMC   All animal procedures in this study 
conformed with the Laboratory Animals Care and Use guidelines published by the United 
States National Institutes of Health and was approved by the Johns Hopkins University 
Animal Care and Use Committee.  PA tissues were surgically dissected and PASMCs 
were enzymatically isolated from the tissues as previously described [311]. Briefly, lungs 
were harvested from male Wistar rats (150–200 g) anesthetized with an overdose of 
sodium pentobarbital (130 mg/kg intraperitoneally). Intrapulmonary arteries of second to 
fourth  generations (800 to 300 µm) were then dissected in a 1.5 mM Ca2+ HEPES-
buffered salt solution (HBSS) containing 130 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 1.5 
mM CaCl2, 10 mM HEPES, and 10 mM glucose (pH 7.2 adjusted with 5 M NaOH). PAs 
were cleaned of connective tissue and cut open to remove their endothelial layers by 
rubbing the luminal surface thoroughly with a cotton swab. For the isolation of PASMCs, 
PA tissues were incubated in cold HBSS for 30 min, and then in HBSS with reduced Ca2+ 
(20 µM) at room temperature for 20 min. PAs were digested in a reduced-Ca2+ HBSS 
containing type I collagenase (1,750 U/ml), papain (9.5 U/ml), bovine serum albumin (2 
mg/ml), and dithiothreitol (1 mM ) at 37 °C for 20 min. After digestion, tissue was 
transferred to Ca2+-free HBSS and the PASMCs were gently dispersed from the tissues 
by trituration in Ca2+-free HBSS. The PASMCs were cultured transiently on 25 mm glass 
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cover slips (18–24 hrs) in HAM’s F-12 media (#10-080-CV,  Mediatech, Inc., VA) with 
0.5% FBS and antibiotics for Ca2+ fluorescence experiments.  
Preparation of protein   Total protein was isolated from PA and other artery tissues, 
including the aorta, mesenteric (MA), renal (RA), femoral (FA), tail (TA), and cerebral 
artery (CA), and the PASMCs were cultured for Western blot analysis of CD38 
expression. Endothelium-denuded PAs were frozen in liquid nitrogen and then pulverized 
with pestle and mortar in the liquid nitrogen. Ground tissues were transferred to a protein 
lysis buffer containing 50 mM Tris, 150 mM NaCl, 300 mM Sucrose, 0.5% NP-40, 1% 
deoxycholic acid, and 0.1% SDS with 5 mM EDTA and HaltTM protease inhibitor 
cocktail (Thermo Scientific, #78430). Tissue and cell lysate were centrifuged by 3,000 g 
at 4 °C for 10 min, and the protein concentrations were measured with the BCA Protein 
Assay Kit (Pierce, #23225).  
Western blot   Protein samples were separated with 10% polyacrylamide gel (20 µg from 
artery tissues and 10 µg from PASMCs per lane), and the separated proteins were 
transferred to an Immobilion®-P PVDF transfer membrane (#IPVH00010, EMD 
Millipore, Billerica, MA) using a tank system filled with transfer buffer containing 3.03 
g/L Tris-base, 14.4 g/L glycine, and 10% methanol (80V, 3 hours, 4 °C). After blocking 
with 5% skim milk in PBS containing 0.0 1% Tween-20 (PBST) at room temperature for 
1 hour, the membranes were incubated overnight with primary antibodies diluted in 3% 
BSA-PBST at 4 °C. The primary antibody for CD38 was diluted by 1:500 (#SC-7049, 
goat-anti rat, Santa Cruz Biotechnology, Inc.) and actin by 1: 5,000 (#SC-1615, goat-anti 
rat, Santa Cruz Biotechnology, Inc.). After a wash in PBST, the membranes were 
incubated with horseradish peroxidase-coupled secondary antibody (#SC-2020, donkey-
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anti goat, Santa Cruz Biotechnology, Inc.) diluted by 1:5,000 in 3% BSA-PBST at room 
temperature for 1 hour, and then washed extensively. Upon incubation of the membrane 
with the enhanced chemiluminenscence substrate (#Pierce Biotechnologies), protein 
signals were detected on autoradiography film and quantified with Gel Logic 200 Image 
System (#Kodak, New Haven, CT). CD38 expression data were normalized with the 
actin level of each sample to correct sample variability.   
 Because of the similarity in size between actin and CD38 protein, the membrane 
was stripped and reprobed after the measurement of CD38. The membrane was gently 
agitated in 100 % acetonitrile for 10 min, submerged in stripping buffer (2% SDS, 62.5 
mM Tris-HCL buffer pH 6.7) containing 100 mM 2-mercaptoethanol, and incubated at 
50 ºC for 25 min. After a wash in PBST, the same protocol with typical a Western blot 
from a blocking step was undertaken. 
Quantitative reverse-transcriptional PCR   Endothelium-denuded PAs frozen in liquid 
nitrogen were mechanically homogenized with pestle and mortar. Total RNA from the 
PA tissues and cultured PASMCs was extracted using an RNeasy® minikit (#74104, 
Qiagen, Valencia, CA), followed by a first-strand cDNA synthesis using random hexamer 
primers and Superscript Ш-reverse transcriptase (#18080-051, Invitrogen, Grand Island, 
NY) according to the manufacturer's protocol. Quantitative real-time RT-PCR (qRT-PCR) 
data was used to quantify the expression of CD38 in PA and other arterial tissues with iQ 
SYBR Green PCR Supermix (#170-8880, Bio-Rad, Hercules, CA) following the 
manufacture’s protocol. Gene-specific primers of qRT-PCR for 18S rRNA and CD38 of 
the following sequences were used: 18S rRNA forward 5′–CGGCTACCACATCCAAGG 
AA–3′ and reverse 5′–AGCTGGAATTACCGCGGC–3′ (accession number: 57149; 
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position: 452-639; expected size: 188 bp), CD38 forward 5′–TGGAGCAAGTCCAAAC 
ACCTGGC–3′, and reverse 5′–CTGGGGTCTCCACACCACCTGA–3′ (accession 
number: 6978628; position: 382-500; expected size: 119 bp). A qRT-PCR protocol, 
consisting of an initial step at 95°C for 5 min, followed by 40 cycles at 95°C for 15 s, 
60°C for 30 s, and 72°C for 1 min, was performed using the iQ5 Multicolor real-time 
PCR detection system (Bio-Rad, Hercules, CA). Absolute copy numbers were calculated 
using standard curves generated from serial dilutions of the known copy number of the 
purified PCR products defined according to each product’s size. All data were 
normalized by the copy number 18s rRNA in each sample to compensate for sample 
variability. 
Calcium Imaging   [Ca2+]i was measured with fluorescent microscopy as previously 
described [311]. Fresh-isolated PASMCs on 25 mm cover-slip incubated overnight were 
loaded with fluo-3 AM (#F1242, Invitrogen, Grand Island, NY) and dissolved in DMSO 
containing 20% pluronic acid for 45 min at room temperature in the dark. Cells were 
washed with a 2 mM CaCl2 tyrode solution containing 137 mM NaCl, 5.44 mM KCl, 1 
mM MgCl2, 10 mM D-glucose, and 10 mM HEPES, with pH 7.4 adjusted with NaOH, 
followed by 20 min of incubation for the deesterification of the cytosolic dye. Fluo-3 
fluorescence, excited at 488 nm and emitted with 515 nm, was detected using a Diaphot 
microscope (Nikon TE2000U) equipped with epifluorescence attachments and a 
microfluometer (PTI, model D-104). Protocols were executed and data collected on-line 
with a Digidata analog-to-digital interface and the pClamp software package (Axon 
Instruments Inc.). Fluorescence intensity (F) was used to calculate the absolute [Ca2+]i 
with the equation: [Ca2+]i =[KD · (F – Fbg )]/(Fmax – F), where Fbg is the background 
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fluorescence and F max is the maximum fluorescence. The value for KD of fluo-3 is 1.1 
µM. Fmax was determined in situ using the Ca
2+ ionophore 4-Bromo-A23187 (#100107, 
Calbiochem, La Jolla, CA) and 10 mM Ca2+, and Fbg was measured in an area devoid of 
cells after Mn2+ quenching. 
Isometric tension measurements in PAs   Isometric contraction of PAs induced by 
agonists were examined by an organ chamber experiment described previously [75]. 
Briefly, rat intralobar PAs (outer diameter: 300–800µm) were surgically harvested, 
endothelium-disrupted by gently rubbing the lumen with a fine wooden stick, and cut into 
ring segments of 4 mm in length. The PA rings were mounted in organ chambers warmed 
at 37°C and filled with Krebs solution (containing 118.3 mM NaCl, 4.7 mM KCl, 1.2 
mM MgSO4, 25 mM NaHCO3, 11.1 mM glucose, 1.2 mM KH2PO4, and 2 mM CaCl2,) 
and gassed with 16% O2-5% CO2 to maintain a pH of 7.4 during the entire experiment. 
Isometric tension was measured using force-displacement transducers (Grass Instruments, 
Quincy, MA), amplified by a PowerLab system controlled by the Chart software 
(ADInstruments Inc. Colorado Springs, CO). After equilibrium under a resting tension of 
approximately 0.8 g for 90 min, three 60 mM KCl-induced vasoconstrictions for 15 min 
each and washouts were performed to attain the stable optimal contraction of PA rings. 
Concentration-dependent responses to Ang II were examined by the cumulative addition 
(0.5 log unit increments) of Ang II into each chamber in the presence or absence of CD38 
inhibitors. All inhibitors were preincubated for 10 min before the addition of AngII. At 
the end of experiments, the PA ring was exposed to phenylephrine (3 x 10-7 M) followed 
by acetylcholine (10-6 M) to verify the disruption of endothelium. Data from PA rings 
with >20% maximal contraction to the phenylephrine were discarded. The Ang II-
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induced isometric tension was normalized to the maximal tension generated by 60 mM 
KCl.  For the estimation of EC50 and maximum response (Emax), the concentration-
response curves were analyzed using a 3-parameter logistic model or Hill equation as 
follows: E= (Emax )/{1+([Agonist]/EC50)
-b}], where E is the response and b is the slope 
factor.  
siRNA knockdown of CD38  Isolated PASMCs in 0.5% FBS-containing HAM’s F-12 
media, incubated overnight, were cultured in 5% FBS-SmGM for 6 days with two cell 
passages. Short interfering RNA (siRNA) for CD38 was commercially purchased from 
Origene (#SR509476A, sequence: 5'-ACCAUACCAUGUAACAAGACUCUCT-3'), 
along with the scrambled control sequence. Prepared PASMCs were transfected with 100 
nM siRNA or scramble control by electroporation using the Amaxa 96-well ShuttleTM 
system (Lonza) and immediately seeded on 25 mm cover-slips in 5% FBS containing 
SmGM and incubated overnight. After 24 hrs, the medium was changed to serum-free 
SmGM for overnight starvation. Intracellular Ca2+ measurements and Western blots were 
performed within 48 hours of the siRNA transfection. 
Chemicals and inhibitors  All chemicals were commercially purchased: Ang II 
( #A9525), nicotinamide (#N0636, an ADP-ribosyl  cyclase inhibitor), 8-Bromo-cADPR 
(#B5416, an antagonist of cADPR), staurosporine (#S-4400, PKC inhibitor), and 
diphenyleneiodonium (DPI, #D2926, NADPH oxidase inhibitor) from Sigma-Aldrich (St. 
Louis, MO); ryanodine (#181-00961, RyRs blocker) from Wako Pure Chemical 
Industries, LTD (Osaka, Japan); trans-Ned-19 (#270-503, a NAADP antagonist) and 
bafilomycin A1(#BML-CM110, a vacuolar-type H+-ATPase inhibitor), from Enzo Life 
Sciences (Farmingdale, NY); apocynin (#178385, NADPH oxidase inhibitor) from EMD 
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millipore (Billerica, MA); and TEMPOL (#4653, ROS scavenger) from TOCRIS 
bioscience (Bristol, UK). The NOX2-specific peptide inhibitor gp91ds-tat (#63818) was 
purchased from ANASpec (Fremont, CA). 
Statistical Analysis   All data are shown as a mean ± S.E.M, calculated by Sigmaplot 11 
(Systat Software Inc). The numbers of duplicates (n) are specified in the text. Statistical 
significance (p<0.05) was assessed with unpaired Student’s t-tests, ANOVA with the 
Holm-Sidak method, or Newman-Keuls post hoc analyses if applicable.  
 
Result 
Profile of CD38 expression in vascular smooth muscle.  
 The expression of CD38 protein in endothelium-denuded rat arteries was detected 
by Western blot. The specificity of the CD38 antibody was verified using a specific 
blocking peptide (SC-7049P, Santa Cruz Biotechnology), which was pre-mixed with 
CD38 antibody (1 antibody: 5 antibody-blocking peptide) and incubated overnight at  
4 C before used. As shown in Figure. 3.1A, CD38 was detected as a single band of 
approximately 45 kDa in the resolved protein samples of PA, the renal artery (RA), and 
the cerebral artery (CA). The signals were completely blocked by the blocking peptide, 
whereas the non-specific signals of 50 kDa were unaffected. The molecular size of CD38 
detected in CA samples was slightly smaller compared to those in PA and RA, 
presumably due to differences in the post-translational modification of glycosylation and 
phosphorylation.  
 We further compared CD38 protein expression in different types of arteries, 
including the aorta (Aor), PA, mesenteric artery (MA), femoral artery (FA), tail artery 
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(TA), RA and CA, as well as in isolated PASMCs (Fig. 3.1B). Immunoblots were 
performed using protein samples from different arteries at the same time. PDVF 
membranes were stripped and reprobed for actin as a loading control for normalization. 
Clear signals of CD38 were detected in PA, RA, CA, and PASMCs, compared to the 
weaker signals in Aor, MA, FA, and TA, with a CD38 expression profile of  
CA>RA=PA>MA>Aor=FA=TA (Fig. 3.1C). qRT-PCR was performed to further 
examine CD38 mRNA expression in the different types of arteries (Fig. 3.1D). CD38 
transcript levels were similar to the protein levels with the exception of a relatively high 
mRNA level in the aorta.  These results indicate that CD38 are differentially expressed in 
different types of arteries, with very clear expression in PA and PASMCs.  
 
Ang II-induced activation of CD38 contributes to PA contraction. 
 To determine the contribution of CD38 activity in vasoreactivity, we examined 
the Ang II-induced isometric contraction of endothelium-denuded rat PA in the presence 
of 20 mM nicotinamide (NA) for the inhibition of CD38 (Fig. 3.2).  Application of 0.1 
nM to 100 nM Ang II activated concentration-dependent contraction expressed as % K-
induced maximum response. Preincubation of PA rings with 20 mM nicotinamide (NA) 
for 20 min significantly reduced the maximal response (control : 89.60±5.06%, n=7; 
nicotinamide: 44.07±4.55%, n=7, p<0.01) and increased the EC50 (control: 1.48±0.25 nM, 
n=7; 3.76±0.53 nM, n=7, p<0.01) as compared to the control  (Fig. 3.2A). Moreover, 
preincubation with 50 μM ryanodine for the inhibition of RyRs also caused a reduction in 
Ang II-induced maximum vasoconstriction (Emax=61.43±15.59%, n=5, p=0.016) 
compared to the control (Emax=111.72±9.78%, n=5), even though it had no significant 
50 
 
effect on EC50 (Fig. 3.2B).  Suppression of Ang II-induced PA contraction by NA and 
ryanodine suggests that CD38 may play an important role in Ang II-induced pulmonary 
vasoconstriction. 
 
Ang II-induced Ca2+ release in PASMCs is mediated in part by CD38. 
 Previous studies have demonstrated that CD38 contributes to agonist-induced 
Ca2+ mobilization in different types of cells and tissues [120,168,172,312]. Hence, we 
characterized Ang II-induced Ca2+ mobilization to determine the involvement of CD38 
dependent mechanisms in PASMCs. The Ang II-induced Ca2+ response was determined 
in PASMCs in the presence extracellular Ca2+, or after Ca2+ containing external solution 
was exchanged with 1 mM EGTA containing Ca2+-free Tyrode solution 100 seconds 
prior to Ang II application to minimize changes in SR Ca2+ stores (Fig. 3.3). Ang II at 
concentrations between 10 nM to 1µM elicited concentration-dependent increases in 
[Ca2+]i, which rose rapidly to the peak and returned to the baseline within 100 seconds. 
The differences between the baseline and the peak  [Ca2+]i (∆[Ca
2+]i) induced by 10 nM, 
100 nM, and 1 µM Ang II were 88.5±32.6 (n= 6), 405.6±51.3 (n=7), and 741.4±122.5 
nM (n=6), respectively, in the presence of 2 mM Ca2+; and 69.6±26 (n=6), 165.5±68 (n=7) 
and 418.6±126.4 nM (n=6), respectively, in the absence of extracellular Ca2+. Ca2+ 
responses activated by 100 nM Ang II were significantly reduced after the removal of 
extracellular Ca2+ (p=0.016). These results clearly suggest that Ang II-induced Ca2+ 
responses consisted of both Ca2+ release and Ca2+ influx in PASMCs. 
 To further elucidate whether AICR is dependent on the cyclase activity of CD38, 
PASMCs were incubated for 20 min with the ADP-cyclase inhibitor NA before the 
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application of 100 nM Ang II under Ca2+-free condition (Fig. 3.4). NA at concentrations 
between 2–20 mM had no significant effect on the basal [Ca2+]i in PASMCs. The kinetics 
of AICR was similar in the presence of NA. In contrast, peak Ca2+ response to 100 nM 
Ang II was reduced by NA in a concentration-dependent manner, with maximum 
[Ca2+]i equal to 469.9±60.2 (n=10), 375±65.8 (n=8, p=N.S.), 268.9±49.3 (n=8, p=0.007), 
221.7±31.6 (n=9, P<0.001), and 152.9±28.6 nM (n=10, p<0.001) at 0, 2 , 5 , 10, and 20 
mM NA respectively. 
 
Knockdown of CD38 expression decreases AngII-induced Ca2+ release in PASMCs.   
 To clarify whether AICR is indeed mediated by activation of CD38 in PASMCs, 
we examined AICR in siRNA-transfected PASMCs. The efficiency of siRNA treatment 
was determined by Western blot (Fig. 3.5A). CD38 protein levels were significantly 
reduced, by 69.05±5.35%, in siRNA transfected PASMCs compared to those in 
scrambled sequence transfected control cells (p=0.006, n=5).  The reduced CD38 
expression was associated with attenuated AICR in the siRNA transfected PASMCs (Fig. 
3.5B). The AICR peaks [Ca2+]i were 1028±114.5 nM in control cells (n=10) and 
552.6±103.1 nM in CD38 siRNA (n=8)(p=0.003). Moreover, the significant reduction of 
AICR caused by 20 mM NA in the scrambled sequence transfected cells (637.8±119.2 
nM, n=8, p=0.012) was not observed in the CD38 siRNA transfected PASMCs 
(574.6±71.9 nM, n=8). Accordingly, the proportion of the reduction in the peak [Ca2+]i 
by 20 mM NA was 37.96±11.59% in the control group, and -3.97±13.02% in CD38 
siRNA transfected PASMCs (p=0.031). These results provide direct evidence that AICR 
is mediated, in part, through CD38 activation in PASMCs. 
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AICR in PASMCs is mediated in part by the cADPR-RyRs and NAADP-TPCs pathway. 
 The cyclase activity of CD38 generates cADPR, which causes Ca2+ release via 
RyRs on the ER/SR in various types of cells, including vascular smooth muscle cells 
[100,141].  To examine the role of the cADPR-RyRs pathway in PASMCs, we 
determined the effects of the specific cADPR antagonist 8-Br-cADPR and ryanodine on 
the AICR in PASMCs (Fig. 3.6). Preincubation of PASMCs with various concentrations 
of 8-Bromo-cADPR for 20 min had no effect on the basal [Ca2+]i, but it caused 
significant reductions in the AICR peaks. The peaks [Ca2+]I elicited by 100 nM Ang II 
were 333.5±32.2 (n=9), 234.2±31.3 (n=6, p=0.026), 198.3±24.4 (n=7, p=0.002), 
185.3±26.5 (n=9, p<0.001), and 190.8±26.3 nM (n= 9, p<0.001) at 0, 0.1, 1, 10, and 100 
µM 8-Br-cADPR, respectively (Fig. 3.6A). An apparent maximum inhibition of 40–50% 
of the control response was reached at 1 µM 8-Bromo-cADPR.  Moreover, inhibition of 
RyRs by 50 μM ryanodine reduced the peak AICR from 299.5±57.3 to 125.4±21.1nM 
(n=9, p=0.034) (Fig. 3.6B). Hence, our data clearly suggest that Ang II-induced increases 
in [Ca2+]i are mediated in part through the activation of ryanodine receptors by cADPR in 
PASMCs. 
 In addition to the cADPR-RyRs pathway, CD38 is responsible for Ca2+ 
mobilization through the activation of catalase, which  generates NAADP targeting the 
two-pore channels (TPCs) that gate the endolysosomal Ca2+ stores [117]. To evaluate the 
contribution of the NAADP-lysosomal Ca2+ pathways, we have examined AICR in the 
presence of the specific NAADP antagonist Ned-19. Our previous study showed that 1 
μM Ned-19 significantly inhibited intracellular Ca2+ release induced by membrane 
permeable NAADP-AM in PASMCs [114]. Preincubation of PASMCs with 1 µM Ned-
53 
 
19 for 20 min significantly reduced the peak Ca2+ response induced by 100 nM Ang II 
from 186.9±44 to 67.6±14.8nM (n=9, p=0.021) (Fig. 3.7A).  Moreover,  3μM 
bafilomycin A1(Baf A1), which blocks the vacuolar-type H+-ATPase and disrupts the 
lysosomal proton gradient for Ca2+ uptake by the H+-Ca2+ exchanger [313,314], 
significantly suppressed AICR (control: 299.5±57.3nM, n=9; Baf A1: 125.4±21.1nM, 
n=8, p=0.014) (Fig. 3.7B). These results suggest that NAADP-mediated Ca2+ release 
from endolysosomal stores also contributes significantly to the Ang II induced Ca2+ 
response in PASMCs. 
 CD38-dependent cADPR-RyRs and NAADP-lysosome pathways may operate 
independently or interdependently to facilitate Ang II induced Ca2+ mobilization. Our 
previous study provided evidence that Ca2+ release from NAADP-sensitive stores is 
amplified by cross-activation of Ca2+ release  from RyRs-gated Ca2+ stores in PASMCs 
[114]. This possibility was examined by inhibiting both pathways with 10 µM 8-Br-
cADPR and 1 µM Ned-19.  The combined inhibitory effect of 8-Br-cADPR and Ned-19 
(peak  [Ca2+]i: control=330.4±40.8nM, n=12; 8-Br-cADPR+Ned-19=157.7±19.5nM, 
n=10, P=0.002) was similar to 8-Br-cADPR or Ned-19 alone, indicating that the effects 
of two inhibitors are non-additive (Fig. 3.7C). These results suggest that the two Ca2+ 
release pathways operate inter-dependently for AICR in PASMCs.  
 
Ang II-induced CD38 activation is mediated by NADPH oxidase-dependent pathways 
in PASMC.  
 We further examined whether Ang II-induced CD38 activation is mediated by the 
PKC-NOX pathway (Fig. 3.8).  Preincubation of PASMCs with the PKC inhibitor 
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staurosporine (STAS, 10 nM)  for 20 min significantly reduced the peak Ca2+ response 
induced by 100 nM Ang II from 332.9±30.9 nM (n=8) to 204.7±34.3 nM (n=9, p=0.019). 
The addition of 20 mM NA to inhibit CD38 did not cause further reduction in the AICR 
(STAS+NA: 163.7±37.2 nM, n=10, p=0.432) (Fig. 3.8A). These results imply that 
activation of PKC is an upstream step in the signaling pathway for Ang II-induced CD38 
activation. 
 To determine the contribution of NOX in Ang II-induced CD38 activation, AICR 
was measured in the absence or presence of the NOX inhibitors apocynin (APC) and 
diphenyleneiodonium (DPI). The peak Ca2+ response elicited by Ang II was significantly 
reduced by 30 µM APC (control: 304±56.9 nM, n=5; APC: 96.7±25.1 nM, n=6, p<0.001).   
Inhibition of CD38 by NA in the presence of APC did not lead to any additional decrease 
in AICR (APC+NA: 111.4±18.1nM, n=6, P=0.002) (Fig. 3.8B). Additionally, Ang II-
induced peak Ca2+ was significantly reduced by 30 µM DPI (control: 333±30.9 nM, n=8; 
DPI: 205.7±34.3 nM, n=9, p=0.019). Likewise, NA did not lead to an additional decrease 
in AICR after inhibition of NOX by DPI (DPI+NA: 164±37.2 nM, n=10, p=0.003) (Fig. 
3.8C). These results suggest that Ang II-induced CD38 activation is mediated by 
activation of NOX. 
 Furthermore, AICR was examined in the presence of the superoxide scavenger 
TEMPOL (TEMP). Preincubation of PASMCs with 100 µM TEMP caused a significant 
reduction in AICR (control: 227.6±33.9 nM, n= 8; TEMP: 120.5±18.4nM, n=9, p=0.007), 
but the addition of NA did not cause further reduction in the response (TEMP+NA: 
92.7±22.4 nM, n=9, p=0.001) (Fig. 3.8D). These data indicate that Ang II-induced 
activation of CD38 is mediated by ROS produced by NOX. 
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Ang II-induced activation of CD38 is specifically mediated by NOX2. 
 To further examine the involvement of specific NOX subtypes in Ang II-mediated 
CD38 activation, we tested AICR in the presence of the small molecule NOX inhibitor 
VAS2870, the NOX1 specific antagonist ML171, and gp91ds-tat, a specific inhibitory 
peptide targeting NOX2. 30 µM VAS2870 had no significant effect on AICR (control: 
275±38.9 nM, n=10; VAS2870: 248±49.5 nM, n=10, p=N.S.) (Fig. 3.9A); likewise, 2 μM 
ML171 did not suppress AICR (control: 326±51.3 nM, n=6; ML171: 315±61.4 nM, n=6, 
p=N.S.) in PASMCs (Fig. 3.9B). 
 In contrast, the pretreatment of PASMCs with 10µM gp91ds-tat caused 
significant reduction in the peak Ca2+ response (control: 364.6±38.7 nM, n=13; gp91ds-
tat: 252.4±24.9 nM, n=13, p=0.045). Furthermore, there was no significant difference in 
the AICR between the gp91ds-tat and gp91ds-tat+NA treated cells (206.5±44.7 nM, n= 8, 
p=0.018). These results suggest that Ang II-induced CD38-dependent Ca2+ release is 
mediated primarily by the activation of NOX2 (Fig. 3.9C). In summary, these results 
suggest that Ang II activates CD38 through the PKC-dependent activation of ROS 





Figure 3.1. CD38 expression in rat pulmonary artery, systemic arteries and 
PASMCs.   (A) Verification of the specificity of CD38 antibody in samples of 
pulmonary artery (PA), renal artery (RA), and cerebral artery (CA) with (right panel) and 
without (left panel) pretreatment of the antibody with a blocking peptide. (B)  An 
immunoblot of CD38 from samples of aorta, PA, mesenteric (MA), renal (RA), femoral 
(FA), tail (TA) and CA arteries. (C) Averaged normalized CD38 protein level in various 
arteries using β-actin for normalization (n=5). (D) Quantitative real-time polymerase 
chain reaction of CD38 mRNA expression from different vascular smooth muscle tissues. 






Figure 3.2. Inhibition of Ang II-induced isometric contraction of PA by 
nicotinamide and ryanodine.  (A) Concentration-dependent curves of Ang II-induced 
PA contraction in the presence or absence of 20 mM nicotinamide (n=7, Left panel). 
Mean maximum contractile force (Emax, right upper panel) and EC50 (right-bottom panel) 
values of Ang II concentration-response curves. Asterisk (*) indicates significant 
difference compared to the untreated control (p<0.001, n=7). (B) Concentration-
dependent curves of Ang II-induced PA contraction in the presence or absence of 50 µM 
ryanodine (n=5)(Left panel). Emax (right upper panel) and EC50 (right-bottom panel) 
values of Ang II concentration-response curves. * indicates significant inhibition by 
ryanodine compared to the untreated control (p=0.016, n=5). EC50 was not significantly 





Figure 3.3. Concentration-dependent increase in [Ca2+]i activated by Ang II in rat 
PASMCs.   (A and B) Average Ca2+ transient ([Ca2+]i) activated by different 
concentrations of Ang II (10 nM, 100 nM and 1 µM) in the presence (2 mM Ca2+) or 
absence (containing 1mM EGTA) of extracellular Ca2+. (C) The average increase ( peak, 
right panel) in [Ca2+]i  induced by different concentrations of Ang II. 






Figure 3.4. Inhibition of AICR by different concentrations of nicotinamide in 
PASMCs   (A) Averaged traces of Ang II-induced Ca2+ transients elicited 100 seconds 
after removal of Ca2+ in the absence or presence of different concentrations (2 mM, 5 
mM, 10 mM, and 20 mM) of the CD38 inhibitor nicotinamide. (B) Averaged peak 
change in [Ca2+]i in the various groups. * indicates significant differences when 







Figure 3.5. Effect of siRNA mediated suppression of CD38 expression on AICR in 
PASMCs.   (A) Left panel shows an immunoblot of CD38 from samples of PASMCs 
transfected with a CD38-targeting siRNA and a control scrambled sequence.  Right panel 
shows the mean CD38 expression data from the two groups after normalization with β-
actin (n=5). * indicates significant decrease in expression compared to the scramble 
control (p=0.006). Note that there was no change in the pattern of the non-specific band 
between the scrambled control and the CD38 siRNA-transfected cells on the blot. (B) 
Left panel shows the mean traces of AICR in the transfected PASMCs in the absence or 
presence of 20 mM nicotinamide (NA). Right panel shows the mean peak [Ca2+]i in the 
control scrambled sequence and CD38 siRNA transfected PASMCs in the absence or 
presence of  20 mM NA. n equals 8 for each group. * indicate significant difference from 
the control group in the absence of NA, and n.s. indicates no significant difference 






Figure 3.6.  Effect of inhibition of cADPR-dependent Ca2+ release on AICR in 
PASMCs.   (A) Left panel shows mean traces of Ang II-induced changes in [Ca2+]i in the 
absence or presence of different concentrations of the cADPR antagonist 8-Br-cADPR. 
Right panel shows the mean data from each group. * indicates significant difference from 
control, 1µM (p=0.002), 10µM (p<0.001) and 100µM (p<0.001)(n=6-9).  (B) Left panel 
shows Ang II-induced changes in [Ca2+]i  in the absence or presence of 50µM ryanodine. 




Figure 3.7 Effect of inhibition of NAADP-dependent pathway on AICR in PASMCs.  
(A) Left panel shows the mean traces of Ang II-induced changes in [Ca2+]i  in the absence 
or presence of the NAADP antagonist Ned-19 (1µM). Right panel shows the peak change 
in [Ca2+]i in each group (n=9, p=0.021).  (B) AICR in PASMCs with or without 
preincubation with the vacuolar H+-ATPase blocker Bafilomycin A1 (3µM)(n=8~9, 
p=0.014). (C) AICR in PASMCs with or without treated with both 8-Br-cADPR (10µM) 







Figure 3.8  PKC-NOX dependent activation of CD38 in PASMCs.  (A) The effect of 
PKC inhibition with staurosporine (STAS, 10 nM) on AICR in PASMCs.  Left panel 
shows the mean traces of AICR in the absence or presence of STAS and STAS+NA (20 
mM).  Right panel shows the mean peak [Ca2+]i in the control (n=8), STAS (n=9, 
p=0.019), and STAS+NA (n=10, p=0.002) treated group. Note that there was no 
additional reduction of [Ca2+]i in the STAS+NA group. (B and C) The effect of the 
NOX inhibitor apocynin (APC, 30μM) and diphenyleneiodonium (DPI, 30μM) on AICR 
in PASMCs. * indicates significant inhibition of AICR by APC (n=6, p<0.001) and 
APC+NA (n=6, p=0.002) compared to control (n=5). There was no significant difference 
between APC and APC+NA treated cells. Likewise, there was significant inhibition of 
AICR by DPI (n=9, p=0.019) and DPI+NA (n=10, p=0.003) compared to the control 
(n=8), while no significant difference between APC and APC+NA treated cells was 
observed. (D) The effect of the ROS scavenger tempol (TEMP, 100 μM) on AICR 
Preincubation of TEMP (n=9, p=0.007) and TEMP+NA+ (n=9, p=0.001), showing a 
significant reduction in AICR, whereas there was no additional inhibition of AICR in 




Figure 3.9. The effects of NOX1 and NOX2 specific antagonist on AICR in PASMCs   
(A and B) The effect of the NOX1 specific inhibitor VAS2870 (30μM) and ML171 
(30μM) on AICR in PASMCs.  Treatment of the specific NOX inhibitors VAS2870 
(n=10) and ML171 (n=6) failed to decrease AICR. (C) The effects of the NOX2 specific 
peptide inhibitor gp91ds-tat (10μM) on AICR in PASMCs. There was a significant 
reduction in AICR with gp91ds-tat (n=13, p=0.045) and gp91ds-tat+NA (n=8, p=0.018) 
treated cells compared to the untreated control.  There was no significant different 




 CD38, through its multifunctional enzymatic activities, generates cADPR and 
NAADP, which contribute to a wide variety of physiologic responses, such as egg 
fertilization [315], vascular smooth muscle contraction [316], insulin secretion [302,317], 
and the asthmatic phenotype in smooth muscle airways [175]. In the present study, we 
found that the expression level of CD38 protein and mRNA in PA smooth muscle is 
relatively higher compared to other vascular smooth muscles. Ang II evokes 
vasoconstriction in PA smooth muscle and induces intracellular Ca2+ release in part 
through both the cADPR- and NAADP-dependent pathways by activating CD38 in 
PASMCs. Furthermore, Ang II induces CD38 activation through the PKC-dependent 
activation of NOX2 in PASMCs. These results provide clear evidence that CD38 is a 
potent regulator of Ca2+ homeostasis in pulmonary vasculature and establish the signaling 
pathway for AICR in PASMCs.   
 CD38 expression has been reported in various types of arteries including systemic 
arteries and PA [122,186,187,188,191,196]. Comparing CD38 expression in different 
arteries, we found that CD38 protein levels vary greatly in different vascular smooth 
muscle tissues, with the highest level in the cerebral artery, followed by the PA and renal 
arteries; whereas the expression in the aorta, mesenteric artery, femoral artery, and tail 
artery are minimal. These observations indicate that CD38 contributes quite differently to 
the physiological functions of various vasculatures. The functions of CD38 have not been 
examined in cerebral arteries; however, they are well characterized in renal arteries and 
arterioles [120,192,197,298,305,316]. It has been shown that CD38-dependent pathways 
mediate significant changes in cytosolic [Ca2+]i and contractile functions in renal afferent 
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arteries and arterioles, and can account for more than 50% of the contractile response 
during Ang II, ET-1 and NE stimulation [197]. Comparable expressions of CD38 protein 
in PA and renal arteries suggest that CD38 may play a similarly significant role in 
pulmonary vasculatures.   
 The important contribution of CD38-dependent pathways in Ca2+ signaling in 
pulmonary vasculature is clearly evident in this study of AICR in PASMCs. Removal of 
extracellular Ca2+ revealed that about 50% of the Ca2+ response is mediated by 
intracellular Ca2+ release, implying that Ang II-induced Ca2+ mobilization is composed of 
extracellular Ca2+ influx and intracellular Ca2+ release. When focusing on the mechanism 
of Ca2+ release in PASMCs, both pharmacological inhibition of CD38 with NA and 
genetic suppression with CD38 siRNA proved to cause significant inhibition of AICR, 
indicating the participation of CD38 in the Ca2+ release process. The specificity of the 
inhibitory effect of NA was verified under our experimental conditions, as NA did not 
cause further reduction of AICR in CD38 siRNA-transfected cells. Moreover, 
nicotinamide caused significant reduction in the sensitivity, and 60% reduction in the 
maximal contraction, induced by Ang II in isolated PAs.  This further suggests a 
significant contribution of CD38 in pulmonary vascular reactivity.  
AICR in PASMCs is mediated in part by the cADPR-dependent Ca2+ release from 
RyR-gated stores and by the NAADP-dependent Ca2+ release from the acidic 
endolysosomes. Antagonism of cADPR with the 8-bromo-cADPR [318] and inhibition of 
RyRs with ryanodine were each effective in suppressing AICR. Inhibition of NAADP 
with its specific antagonist Ned-19 [319], or depleting endolysosomal Ca2+ stores by 
disrupting the H+ gradient for H+-Ca2+ exchange with the vacuolar H+-ATPase inhibitor 
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Baf A1 [320], also reduced AICR. These results suggest that Ang II stimulates both the 
cyclase and catalase activities of CD38 for the production of cADPR and NAADP, 
respectively.    
It is interesting to note that the cADPR- and NAADP-dependent mechanisms 
operate interdependently during AICR because the suppression of AICR by co-inhibition 
of cADPR and NAADP remain comparable to the inhibition of either cADPR or NAADP 
alone. These results are consistent with previous findings including ours on the cross-
activation of RyRs by NAADP-mediated Ca2+ release in PASMCs [114,121,200], 
implying that NAADP-channels are coupled with Ca2+ release via RyRs, and that cADPR 
may sensitize RyRs for the cross-activation by Ca2+-induced Ca2+ release under 
physiological stimulation. The remaining AICR in PASMCs, after co-inhibition of 
cADPR and NAADP, was likely due to IP3R-gated Ca
2+ release mediated by the well-
recognized PLC-IP3 pathway of angiotensin receptors [321,322]. 
 An increasing amount of evidence suggests that Ang II enhances ROS production 
through the activation of NOX, contributing to the Ca2+ response in vascular smooth 
muscle cells [323]. Several studies have demonstrated that CD38 activity is regulated by 
redox-state and oxidative stress [191,194,309,324,325]. However, the mechanism of Ang 
II-induced CD38 activation in PASMCs has not been established. This study 
demonstrates that Ang II activates CD38 in PASMCs via ROS generation by NOX. This 
is based on the finding that AICR, which is mediated by the activation of CD38, was 
inhibited significantly by the NOX inhibitors APC and DPI, and the ROS scavenger 
TEMPOL. Inhibition of CD38 with NA in the presence of the NOX inhibitors or the ROS 
scavenger did not further suppress the Ang II-induced Ca2+ response in PASMCs, 
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suggesting that ROS plays a pivotal role in the activation of CD38 in PASMCs. These 
observations are consistent with findings on renal afferent arterioles and cardiac 
myocytes that Ang II stimulates NOX to generate ROS, leading to enhanced ADP-ribosyl 
cyclase activity [305,326]. 
There are five NOX homologues (NOX1–5) with different subunit compositions 
and localizations [323,327].  It has been reported that Ang II-induced ROS production in 
vascular smooth muscle cells from large arteries is mediated by NOX1 [328] and, in 
resistance arteries, is mainly depend on NOX2 [307].  NOX1 and NOX2 can be activated 
through Rac1 [323,327,329].  It has been shown that ET-1 stimulates Rac1-NOX1-
dependent ROS production to activate CD38 in coronary arteries [329].  NOX2 can also 
be activated by PKC dependent phosphorylation of p47phox to facilitate the assembly of 
the oxidase complex [323].  We found that preincubation of PASMCs with specific 
NOX1 inhibitors ML171 [330] and VAS2870 [331] had no significant inhibitory effect 
on AICR.   In contrast, the NOX2 specific peptide inhibitor gp91ds-tat caused a 
significant decrease in AICR but no further reduction with inhibition of CD38 by NA, 
indicating that the Ang II-induced activation of CD38 is specifically mediated by NOX2. 
Moreover, inhibition of PKC with STAS also suppressed AICR.  These results, therefore, 
are consistent with Ang II-induced CD38 activation through the PKC-NOX2-ROS 
pathway to elicit Ca2+ release in PASMCs.    
In this study, NA was used as a CD38 inhibitor. Although NA may have other 
non-specific effects, NA has been widely used and accepted for the purpose of CD38 
inhibition in previous as well as recent studies [167,298,332]. Since the activity of CD38 
is dependent on the substrate NAD+, high concentration of the NAD+ analog operates as a 
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competitive antagonist to inhibit the CD38 enzyme activity. In fact, recent studies on 
novel CD38 inhibitors have continuously designed analogs, which are structurally 
derived from NAD+ [333]. Despite the high concentration used in this study, the cell 
morphology and resting [Ca2+]i were not altered in the presence of NA during Ca
2+ 
imaging experiment, indicating that NA does not cause significant disturbance in Ca2+ 
homeostasis. A recent study demonstrated that apigenin, a flavonoid, is a specific 
inhibitor for NADase activity of CD38 in vivo [334]. However, apigenin could not 
applicable for AICR measurement due to its toxicity during the preincubation. 
Nonetheless, NA could not cause additional reduction in AICR when CD38 was 
knockdown by siRNA suggesting that NA is useful tool in our research on CD38 
dependent Ca2+ release in PASMC.  
  In conclusion, this study systematically characterized the mechanism of Ca2+ 
release induced by Ang II in PASMCs and demonstrated that it is in part mediated by 
CD38 activation through NOX2-dependent ROS production, leading to the synergistic 
Ca2+ release from cADPR- and NAADP-gated Ca2+ stores. These findings, hence, 
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CHRONIC HYPOXIA REGULATES THE EXPRESSION AND ACTIVITY OF 




 The pathophysiological changes in chronic hypoxia-induced pulmonary 
hypertension (CHPH) are multi-factorial and complex. Accumulating evidence suggests a 
role for aberrant alterations in the regulation of intracellular Ca2+ of pulmonary arterial 
smooth muscle cells (PASMCs). Previous studies have reported elevation of [Ca2+]i in 
PASMCs due to enhanced Ca2+ influx in CHPH, but the changes of intracellular Ca2+ 
release under chronic hypoxia (CH) have not been examined. This study characterized 
the CH-induced alterations in the expression and functions of CD38, a multi-functional 
enzyme that produces the Ca2+ mobilizing messengers cyclic ADP-ribose and nicotinic 
acid adenine dinucleotide phosphate in PASMCs. The expression of CD38 protein and 
mRNA were both significantly upregulated in the PA smooth muscle of CH rats. This 
upregulation of CD38 in PA of CH rats was time-dependent, observed after 3–7 days of 
hypoxic exposure and declining after 3 weeks of CH. NADase activity of CD38 in PA 
smooth muscle was significantly increased, whereas the same activity in whole lung was 
decreased after 1-week hypoxia, suggesting specific CD38 upregulation in hypoxic PA. 
Angiotensin II-induced Ca2+ release (AICR), which is mediated in part by CD38, was 
significantly increased in PASMCs isolated from CH rats. The difference between AICR 
in PASMCs of normoxic and 1-week CH rats was completely abolished by the CD38 
inhibitor nicotinamide. The CH-induced upregulation of CD38 expression and activity 
were due to the direct effect of hypoxia on PASMCs. In vitro exposure of PASMCs from 
normoxic rats to hypoxia for 3 days caused significant increase in CD38 expression and 
enhancement in AICR, which was equalized by nicotinamide. Sequence analysis of the 
putative promoter region of CD38 gene found multiple putative binding motifs of nuclear 
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factor of activated T-cells (NFAT). CH-induced upregulation of CD38 expression in 
isolated PASMCs was inhibited by the specific NFAT-inhibitor VIVIT and the 
calcineurin inhibitor cyclosporine A, indicating that CH-induced CD38 upregulation in 
PASMCs is mediated by the calcineurin/NFAT-pathway. Moreover, the expressions of 
the NAADP-sensitive channels (TPC1 and TPC2) were significantly increased in the PA 
smooth muscle of CH rat. All these results clearly indicate that CH has a profound effect 
on CD38-dependent mechanisms that may play crucial roles in the alterations of Ca2+ 
homeostasis in PASMCs. 
 
Introduction 
 Chronic alveolar hypoxia (CH), as occur in high altitude inhabitants or patients 
with chronic pulmonary diseases such as COPD, triggers the development of pulmonary 
hypertension (PH). CH-induced pulmonary hypertension (CHPH) is characterized by 
increased vascular tone, altered vasoreactivity, and profound vascular remodeling, 
leading to an increase in pulmonary vascular resistance, right heart hypertrophy and 
eventually right heart failure [335,336,337]. The mechanism for the pathogenesis of 
CHPH is complex and multifactorial [338], but many of the pathophysiological changes 
in the pulmonary vasculature in CHPH is clearly associated with the alteration in Ca2+ 
homeostasis of pulmonary arterial smooth muscle cells (PASMCs) [238,239]. It is well 
recognized that CH leads to the elevation of cytoplasmic [Ca2+]i in PASMCs via many 
different mechanisms; for example, downregulation of voltage-gated K+ (Kv) channels 
[66,70,247,339], enhanced Ca2+ entry mediated through upregulation of store-operated 
Ca2+ entry (SOCE) [52,238,265,279], receptor-operated Ca2+ entry [38,238,340], 
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mechanosensitive cation channels  [37,39], acid-sensing ion channels (ASIC) 
[278,279,280], voltage-dependent Ca2+ channels (VDCC) [35,276], and Ca2+-activated 
Cl-  channels [75]. However, there is very limited information on the effects of CH on 
intracellular Ca2+ release pathways in PASMCs. 
 CD38 is a multifunctional enzyme, that syntheses the Ca2+ mobilization second 
messenger cADPR and NAADP, which are endogenous ligands of ryanodine receptors 
(RyRs) of sarcoplasmic reticulum and NAADP-sensitive channels of endolysosomes, 
respectively [144,341]. Hence, it plays important roles in regulating intracellular Ca2+ 
release.  Moreover, Ca2+ release from RyRs may further enhance Ca2+ influx by initiating 
SOCE [342,343], and activating Ca2+-activated Cl- channels (CaCC) to cause membrane 
depolarization and activation of VDCC [74,76]. However, only few studies provided 
evidence that CD38 plays a role in [Ca2+]i regulation in response to hypoxia in PASMCs. 
Previous studies had shown that acute hypoxia promotes accumulation of cADPR 
causing Ca2+ release from RyR-gated Ca2+ stores to initiate pulmonary vasoconstriction 
[191,324]. Indeed, it has been proposed that CD38 acts as a redox sensor for HPV. A 
reduction of β-NAD+:β-NADH ratio during hypoxia stimulates cyclase activity and 
inhibits hydrolase activity of CD38, leading to the accumulation of cADPR to cause 
intracellular Ca2+ release. However, this hypothesis is challenged by a recent study which 
showed that HPV in isolated PAs requires neither cADPR- nor NAADP-dependent Ca2+ 
release in the absence of preconstriction, but rather is mediated by SOCE independent of 
CD38 mediated Ca2+ release [290]. Besides these studies, there is no published record on 
the regulation of CD38 expression and activity by CH in PASMCs.  
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In this study, we tested the hypothesis that CD38-dependent mechanisms play a 
crucial role in the alterations of Ca2+ homeostasis in PAs and PASMCs of CH rats.  We 
examined CD38 expression and the CD38-dependent angiotensin II (Ang II) induced 
Ca2+ release (AICR) in PAs of CH rats and hypoxic PASMCs, as well as the 
transcriptional regulation of CD38 by CH. Furthermore, we examined the expression of 
the NAADP-sensitive channels (two-pore channels, TPC1 and TRPC2) in PAs of CH rats, 
as to understand the regulation of Ca2+ release mediated by CD38 under CH. 
 
Methods 
Animal care   All animal procedures were compliant with the Guide for the Care and Use 
of Laboratory Animals published by the United States National Institutes of Health and 
was approved by the Johns Hopkins University Animal Care and Use Committee. Male 
Wistar rats (150–200g) were commercially purchased from Harlan laboratories. 
Hypoxia exposure   Adult male rats were placed in hypoxic chamber (10% O2) for 
maximum 3–4 weeks (wk) as described previously [344]. Hypoxic air, a mixture of N2 
and room air, was continuously flushed into chamber. O2 concentration in the chamber 
was continuously monitored. Food and water were replenished two times a week. PA 
tissues were harvested at different time-point based on the experimental protocol. Isolated 
PASMCs from hypoxic rats were placed in a modular incubation chamber (Billups-
Rothenberg Inc.) filled with 4% O2 hypoxic air. PASMCs from normoxic rat were 
cultured under 2% O2 for 3 days to induce the hypoxic response. 
Preparation of rat PA tissues and PASMCs   Intralobar PA tissues and PASMCs were 
isolated as described in Chapter II. Briefly, rats were anesthetized using sodium 
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pentobarbital (130 mg/kg intraperitoneally) and the second to the fourth generations (800 
to 300 µm) of intralobar PA were harvested in HEPES-buffer. After endothelium-
denudation, PASMCs were enzymatically digested and cultured in HAM's F-12 media 
overnight. PASMCs were platted on 25 mm glass cover slips and transiently cultured for 
12–18 hours before the Ca2+ fluorescence experiments. PASMCs were cultured in 
Smooth muscle Cell Basal Medium (#CC-3181, Lonza, MD) with 5% FBS and 
antibiotics for 3 days after overnight incubation with HAM's F-12 media for protein and 
mRNA determination. 
Western blot   Total protein was isolated from PA tissues and cultured PASMCs for 
Western blot analysis of CD38 expression as previously described in Chapter II. Briefly, 
tissue and cell lysates were resolved by 10% polyacrylamide gel and transferred to PVDF 
transfer membrane using a tank system filled with transfer buffer.  After blocking, the 
membrane was incubated with primary antibodies diluted in 3% BSA-PBST at 4 °C 
overnight. The primary antibody for CD38 was diluted by 1:500 (#SC-7049, goat, Santa 
Cruz Biotechnology, Inc.), TPC1 by 1:500 (#ab80961, rabbit, Abcam), TPC 2 by 1:2,500 
(#ACC-072, rabbit, Alomone Labs), actin by 1:5,000 (#SC-1615, goat, Santa Cruz 
Biotechnology, Inc.), and β-actin by 1:50,000 (#A1978, mouse, Sigma-Aldrich).  After 
wash, membranes were incubated with horseradish peroxidase-coupled secondary 
antibody diluted by 1:5,000 for CD38 and actin (#SC-2020, donkey anti-goat, Santa Cruz 
Biotechnology, Inc.), 1:5,000 for TPC1/2 (#SC- 2313, donkey anti-rabbit, Santa Cruz 
Biotechnology, Inc.) and 1:50,000 for β-actin (#NA931V, sheep anti- mouse, GE 
healthcare UK limited) in 3% BSA-PBST. Protein signals were detected by enhanced 
chemiluminescence (Pierce) on autoradiography film and quantified by Gel Logic 200 
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Image System (Kodak, New Haven, CT).  After CD38 determination, the membrane was 
stripped and reprobed for actin/β-actin in the same blot as previously described in 
Chapter 3. 
Quantitative reverse-transcription PCR   Total RNA was extracted from endothelium-
denuded PA tissues and cultured PASMCs using RNeasy® minikit (#74104, Qiagen, 
Valencia, CA) and followed by first-strand cDNA synthesis using random hexamer 
primers and Superscript III-reverse transcriptase (#18080-051, Invitrogen, Grand Island, 
NY) according to the manufacturer's protocol. Quantitative real-time RT-PCR (qRT-PCR) 
using iQ SYBR Green PCR Supermix (#170-8880, Bio-Rad, Hercules, CA) was used to 
quantify the expression of CD38 in PAs and PASMCs. The sequence for the gene-
specific primers was described in table 1. The copy number of target mRNA expression 
was normalized by the copy number of TATA-box binding protein (TBP) as an internal 
control. 
Ca2+ imaging for intracellular Ca2+ release   [Ca2+]i was measured with fluorescent 
 
Table 4.1. Primer sequence for qRT-PCR 
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microscopy as previously described in Chapter II. Briefly, fluo-3 AM (#F1242, 
Invitrogen, Grand Island, NY) was loaded into isolated PASMCs on 25 mm cover-slip 
and incubated for 45 min at room temperature in the dark. After washed and incubation 
for deesterification of cytosolic dye, Fluo-3 was excited at 488 nm and the emitted light 
at 515 nm was detected by inverted microscope (Diaphot, Nikon TE2000U) equipped 
with epifluorescence attachments and a microfluometer (PTI, model D-104). PASMCs 
were pretreated with the CD38 inhibitor nicotinamide for 20 min. To examine 
intracellular Ca2+ release, Ca2+ containing (2 mM) Tyrode solution was changed with 
Ca2+-free Tyrode (containing 1 mM EGTA) 100 seconds prior to the application of Ang 
II. Fluorescence intensity (F) was used to calculate the absolute [Ca2+]i using the equation: 
[Ca2+]i =[KD · (F – Fbg )]/(Fmax – F). Fbg is the background fluorescence, Fmax is the 
maximum fluorescence, and KD of fluo-3 is 1.1. Fmax was determined in situ using the 
Ca2+ ionophore 4-Bromo-A23187 (#100107, Calbiochem, La Jolla, CA) and 10 mM Ca2+, 
and Fbg was measured in a cell-free area after Mn
2+ quenching  
Identification of putative transcription factor binding motifs in CD38 gene    Rat CD38 
promoter region sequence was pulled from the Rat Genome Database, and the ALGGEN 
PROMO, which uses TRANSFAC database for transcription factor binding sites, was 
utilized to determine putative transcription factor binding motifs for NFAT, HIF-1, NF-
κB, and CREB-like motif. The sequences were manually validated for the presence of 
putative HIF-1 (ACGTG or CACGT), NFAT (GGAAA or TTTCC), NF- κB 
(GGGATTCC or GGGGC) and CREB-like (TGGCGTCA) binding core motif. 
Determination of NADase activity   Measurement of NADase activity was performed by 
a fluorometric method (by Dr. Eduardo Chini’s laboratory) as previously described 
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[345,346]. The enzyme activity was determined by measuring change in fluorescence 
with excitation (300 nm) and emission (410 nm) wavelengths in the presence of the 
NADase substrate 1-etheno-NAD. Tissue samples from PA and whole lung tissue with a 
final protein concentration of 0.5 mg per ml were incubated in a medium containing 0.2 
mM 1-etheno-NAD, 0.25 M sucrose, and 40 mM Tris–HCl (pH 7.2) at 37°C. After 
baseline fluorescence was recorded, 80 μM of 1-etheno-NAD was added to start the 
reaction and fluorescence was recorded for 200 sec. The activity was calculated as the 
fluorescence units per unit time normalized by the amount of protein in the samples 
(unit/sec/mg protein). 
Chemicals and inhibitors   All chemicals were commercially available to be purchased; 
Ang II (#A9525, Sigma-Aldrich), nicotinamide (#N0636, Sigma-Aldrich), cell-permeable 
VIVIT (#480401, Calbiochem) and cyclosporine A (#C-6000, LC Laboratories). 
Statistical Analysis   All data are expressed as mean ± S.E.M. The numbers of replicates 
(n) are specified in the text. Statistical significance (p<0.05) was assessed by unpaired 
Student’s t-tests or ANOVA with Holm-Sidak method if applicable. 
 
Results 
CD38 expression in PA smooth muscle tissue was increased in PA tissue from CH rat 
for 3–4wk.  
 As the first step of investigating the effects of CH on CD38 dependent 
mechanisms, we determined the expression of CD38 protein and mRNA in PAs of 
normoxic and CH rats (Fig. 4.1A). Immunoblot analysis showed that the expression of 
CD38 protein in endothelium-denuded PAs of 3–4 week CH rats (1.21±0.06) was slightly 
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but significantly increased compared to that of normoxic rats (1.00±0.07) (n=12, 
p=0.042). The CD38 mRNA level, quantified by qRT-PCR, was also significantly higher 
in the PA of CH rats. (CH: 0.199±0.032; normoxia: 0.094±0.019, n=7, p=0.016).  
 To examine the possible changes in the functional activity of CD38 caused by CH, 
AICR was determined in PASMCs isolated from normoxic control and 3–4 week CH rats 
(Fig. 4.1B). Intracellular Ca2+ release was elicited by 100 nM Ang II 100 seconds after 
removal of extracellular Ca2+. Similar to the expression of CD38 protein, the peak 
[Ca2+]i ([Ca2+]i, peak - [Ca2+]i, baseline) of AICR was slightly but significantly elevated  in 
PASMCs of CH rat (353.6±26.8 nM , n=11) compared to those of normoxic control 
(274.3± 21.6 nM, n=12) (p=0.05). These results implied that CH increases the expression 
and functional activity of CD38 in PASMCs.  
 
CD38 expression and activity in PA were greatly enhanced during the early 
development of CHPH.   
 A previous study showed spontaneous rhythmic contractions, spike-like 
membrane depolarization, and elevated resting [Ca2+]i in the PAs of rats after 1 weeks of 
CH [281]. These activities were blocked by ryanodine or cyclopiazonic acid and subsided 
after prolonged CH exposure (4 week). These results indicate that intracellular Ca2+ 
release contributes to spontaneous contraction of PA during the early development of 
CHPH.  
 To examine the possible changes in CD38 dependent mechanism during the early 
stage of CHPH development, we examined the time-course of change in CD38 
expression in PAs of CH rats. CD38 protein expression in PAs was determined after 0, 1, 
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2, 3, and 7 days of CH exposure, with normalized values of  1.03±0.15, 0.89±0.12, 
1.63±0.26, 2.00±0.13, 2.52±0.22, respectively  (n=5 for each group) (Fig. 4.2A). CD38 
protein levels significantly increased by day 3 and day 7 (p=0.001 and p<0.001, 
respectively), compared to the day 0 control. Similar time-course changes were found in 
the mRNA level of CD38 in the PAs after CH exposure (day 0: 0.27±0.05; day 1: 
0.19±0.03; day 2: 0.34±0.09; day 3: 0.57±0.05; and day 7: 0.88±0.26, n=5 for each group) 
(Fig. 4.2B). The mRNA level of CD38 was significantly upregulated in PAs after 3 and 7 
days of CH exposure (p=0.003 and p=0.008, respectively).  These results indicate that the 
CH upregulates the expression of CD38 protein and mRNA of PA smooth muscle in a 
time-dependent manner. The 2–3 fold increase in CD38 expression after 3 to 7 days of 
hypoxic exposure, as compared to the marginal increase in 3–4 weeks CH suggests that 
CD38 may be more involved during the early development of CHPH. 
 
NADase activity was increased in PA smooth muscle from hypoxic rat.   
 To examine whether the upregulation of CD38 expression by CH was associated 
with increased enzymatic activity, NADase activity (i.e. CD38) was measured 
(collaboration with Dr. Eduardo N. Chini, in Mayo Clinic, Rochester, MN) (Fig.4.2C).  
NADase activity was significantly increased in PAs of 1-week CH rats, with 6.61±2.03 
units/sec/mg protein in normoxic control and 18.38±3.15 units/sec/mg protein in CH PAs 
(n=9, p=0.006). In contrast, NADase activity was significantly lower in whole lung tissue 
in hypoxic rat (38.03±2.33 units/sec/mg protein) compared to normoxic control 
(51.33±5.02 units/sec/mg protein) (n=6, p=0.037).  These data suggest that the effects of 
CH on CD38 activity, and perhaps expression, are different in the whole lung and PA 
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tissues. We also examined the weight of whole lung tissue, and right heart hypertrophy 
(RV/(LV+S)) from normoxic and CH rats (Fig. 4.3). The weight of lungs of 1 week 
hypoxic rat (1.29±0.10 g, n=9) was significantly higher than that of normoxic control 
(0.93±0.05 g, n=9) (p<0.001, respectively). Likewise, the weight of PA smooth muscle 
tissue of 1 week hypoxic rat (0.0461±0.00206 g, n=16) was significantly higher than the 
normoxic control (0.0351±0.00235 g, n=16, p=0.001). RV/(LV+S) was also significantly 
higher in 1-week hypoxic rats (control: 27.63±0.73 %, n=12; CH: 44.29±0.80 %, n=12, 
p<0.001). These results implicate that the 1 week hypoxia exposure causes the 
development of CHPH including right heart hypertrophy, pulmonary vascular remodeling, 
and alteration in CD38 activity.   
 
AICR was increased in PASMCs of 1 week hypoxic rats. 
 To examine the CD38 dependent Ca2+ release processes, AICR was determined in 
PASMCs of normoxic control and 1 week hypoxic rats (Fig. 4.4). Ca2+ release induced 
by 100 nM Ang II was examined and recorded in the presence or absence of 20 mM 
nicotinamide (NA) (Fig. 4.4A). AICR was significant greater in hypoxic PASMCs 
(455.3±63.3 nM, n=12) than in normoxic PASMCs (289.9±32.3 nM, n=9, p=0.04). The 
Ca2+ response was significantly suppressed by inhibition of CD38 with NA (normoxic: 
124.3±20.4 nM, n=8, p<0.001; CH: 115.4±15.7 nM, n=9, p=0.037), and there was no 
difference between the two groups in the presence of NA (Fig. 4.4B). The percent 
inhibition of AICR by NA was significantly greater in the hypoxic cells (74.65±4.16%) 
compared to the normoxic cells (55.61±6.16%, p=0.014) (Fig. 4.4C). These results 
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suggest that the CD38-dependent Ca2+ release activated by Ang II was potentiated in 
PASMCs of 1 week CH rats. 
 
Hypoxia directly enhanced CD38 expression and activity in PASMCs of normoxic rats. 
 Upregulation of CD38 expression in the CH rat model could be related to multiple 
factors.  To determine whether hypoxia induces CD38 expression through a direct effect 
on PASMCs, PASMCs isolated from normoxic rat were exposed to 21 or 2% O2 for 3 
days, and the expression of CD38 in the two groups were compared (Fig. 4.5A). Western 
blot analysis showed that CD38 protein level was significantly increased in the hypoxia 
PASMCs (2.19±0.35, n=5) compared to the normoxic control (1.25±0.05, n=5, p=0.025). 
The CD38 mRNA level of hypoxic PASMCs (5.43±0.13×105) was also significantly 
higher than that of normoxic cells (2.07±0.42×105, n=5, p=0.036). These data clearly 
indicate that hypoxia exerts a direct effect on PASMCs to upregulate the expression of 
CD38. 
 AICR was performed to examine the functional changes in CD38 activity caused 
by the direct effect of hypoxia (2% O2, 3 days) in PASMCs (Fig. 4.5B). Peak [Ca2+]i 
induced by Ang II (100 nM) was 325.2±16.6 nM in normoxic (n=14) and 593.3±77.0 nM 
in hypoxic PASMCs (n=15) in the absence of NA; and 152.9±21.0 nM in normoxic (n=7) 
and 111.5±31.9 nM in hypoxic PASMCs (n=6) after CD38 was blocked by 20 mM NA.  
AICR was significant greater in the hypoxic PASMCs compared to the normoxic control 
(p=0.002).  The Ca2+ response was significantly suppressed by the inhibition of CD38 
(p<0.001 for both), but there was no significant difference between the normoxic and 
hypoxic PAMSCs in the presence 20 mM NA. The percent inhibition of AICR by 20 mM 
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NA was 81.21±5.37% in hypoxic PASMCs and 52.98±6.47% in normoxic cell.  The 
percent inhibition was significantly greater in the hypoxic PASMCs (p=0.007). These 
data show that the upregulation of CD38 expression in PASMCs caused by direct 
hypoxia exposure was associated with enhanced CD38-dependent Ca2+ response. 
 
NFAT is putative regulatory transcription factor for CD38 expression in rat PASMCs. 
 To further investigate the molecular mechanism of CD38 upregulation by hypoxia, 
the putative binding sites for transcription factors in the promoter region of rat CD38 
gene were explored in a 3.0 kbp  5'-UTR promoter region of CD38 (Fig. 4.6). We found 
that there are ten NFAT, three HIF, two NF-κB, and one CREB-like putative binding- 
motifs in the region, indicating that these transcriptional factors could be involved in the 
upregulation of CD38 expression by hypoxia. 
 
CH-induced CD38 upregulation was dependent on the calcineurin/NFAT pathway.  
 Since there are multiple putative NFAT binding sites in the promoter region of the 
CD38 gene, we tested the involvement of the calcineurin/NFAT pathway in the hypoxia-
induced upregulation of CD38 in PASMCs.  Expression of CD38 protein was examined 
in PASMCs isolated from normoxic rat and cultured under hypoxia (2% O2) for three 
days in the absence or presence of the peptide inhibitor of NFAT activation VIVIT (3 µM) 
or the calcineurin inhibitor cyclosporine A (Cyc A, 5 µM) (Fig. 4.7). Semi-quantitative 
Western blot analysis showed that the relative CD38 protein level was 0.984±0.0632 in 
normoxic control, 0.844±0.0603 in VIVIT treated, and 0.808±0.0477 in Cyc A treated 
normoxic cells (n=5). It was not significantly altered by VIVIT and Cyc A treatment for 3 
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days.  CD38 was significantly increased in the hypoxic cells (1.562±0.0633, p=0.005) 
compared to normoxic control. The hypoxia-induced increase in CD38 protein was 
blocked by VIVIT (1.131±0.167, p<0.001) and Cyc A (1.070±0.199, p<0.001). There 
was no significant upregulation of CD38 by hypoxia in the presence of both inhibitors. 
These results suggest that the hypoxia-induced upregulation of CD38 in PASMCs is 
mediated by calcineurin/NFAT-dependent pathway. 
 
CH alters the expression of NAADP-sensitive Ca2+ release channels in PA smooth 
muscle. 
 To further elucidate the changes in the CD38-dependent mechanism in PASMCs 
under CH exposure, we examined the expression of the NAADP-sensitive Ca2+ channels 
TPC1 and TPC2 in PAs of normoxic and CH rats (Fig. 4.8). Semi-quantitative Western 
blot analysis found that the expression of TPC1 protein in PA tissue of 3–4 week hypoxic 
rat (0.65±0.21, n=6) was significantly increased compared to that of normoxic rats 
(0.14±0.05, n=6, p=0.031) (Fig. 4.8A). Similar increase in TPC2 expression was 
observed in hypoxic PAs (normoxic: 0.94±0.15, n=6; CH: 1.75±0.26, n=6, p=0.021). We 
also examined the expression of TPC1 and TPC2 protein in PAs of rats exposed to CH 
for different durations (Fig. 4.8B). The relative TPC1 protein level was 0.88±0.12 in day 
0, 0.99±0.19 in day 1, 1.18±0.25 in day 2, 1.27±0.18 in day 3 and 1.47±0.29 in day 7 
(n=5 rats for each time-point). The expression level of TPC2 protein was 1.49±0.52 in 
day 0, 1.58±0.41 in day 1, 4.49±0.99 in day 2, 6.12±1.45 in day 3 and 5.24±0.98 in day 7 
(n=5 rats for each time-point). The TPC2 protein level was significantly increased in PAs 
of rats after 2, 3, and 7 days of CH (p=0.028, p=0.010, and p=0.033, respectively) 
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compared to that of normoxic control. TPC1 protein showed a tendency of increase while 
there is no statistical significance in the hypoxic PA tissue. In contrast, mRNA level of 
TPC1/2 in PA tissue was not significantly changed in CH rats compared to the normoxic 
control. These results suggest that CH exposure induces TPC1/2 protein expression in PA 






Figure 4.1. Upregulation of CD38 in PA smooth muscle tissue and enhancement of 
AICR in PASMCs of 3–4 week CH rat (A) Upper panel shows representative 
immunoblot of CD38 and β-actin in PA samples of normoxic (Nx) and CH (Hypx) rats.  
Lower panels show mean data of semi-quantitative Western blot and quantitative real-
time polymerase chain reaction (qRT-PCR) analysis of CD38 protein and mRNA in PA 
smooth muscle of 3–4 week hypoxic and normoxic rats. Asterisk (*) indicates significant 
increase compared to Nx rats (n=7 for each groups, P=0.042 for CD38 protein and 
p=0.0014 for CD38 mRNA). (B) Mean traces of An II-induced increase in [Ca2+]i (left 
pannel) and mean peak [Ca2+]i elicited in PASMCs of normoxic (n=11) and CH rats 
(n=12) (right panel). * indicates significant increase in Ca2+ response compared to 





Figure 4.2. CD38 expression and activity in PA smooth muscle of rats after different 
periods of CH (10% O2) exposure   (A) Western blot analysis of CD38 protein 
expression in PA of rat at different time-points of CH exposure. * indicates that CD38 
protein increased significantly in day 3 (n=5, p<0.001) and day 7 (n=5, p<0.001) 
compared to day 0. (B) Conventional RT-PCR (upper panel) and qRT-PCR (lower panel) 
analysis of CD38 mRNA expression in PA tissue. * indicates that CD38 mRNA 
increased significantly in day 3 (n=5, 0.004), and day 7 (n=5, p<0.001) compared to day 
0. (C) NADase (i.e. CD38) activity measured in whole lung lobe and PA smooth muscle 
of normoxic and 1wk hypoxic rats.* indicates that NADase activity in PAs of 1week 
hypoxic rat was significantly increased (n=9, p=0.006), while the activity in whole lung 
lobe tissue of 1wk hypoxic rat was significantly decreased (n=6, p=0.037), compared to 







Figure 4.3. CH-induced lung, PA and cardiac remodeling   (A and B) The weight of 
whole lung lobe and PA of 1 week hypoxic rat. * indicates significant difference in lung 
lobe (n=9, p<0.001) and PA tissue (n=16, p=0.001) compared to Nx control (n=9 and 
n=16, respectively). (C) Measurement of RV/(LV+S) for right heart hypertrophy. 
* indicates that RV/(LV+S) was significantly higher in hypoxic rats (n=12) compared to 





Figure 4.4.  CH-induced increase in AICR mediated by CD38   (A) Mean trace of 
[Ca2+]i by 100nM Ang II in PASMCs from 1wk Hypx and Nx rat in the presence of 20 
mM nicotinamide (NA) to inhibit CD38. (B) Mean peak [Ca2+]i of AICR. Double 
asterisk (**) demonstrates the significant enhancement of peak [Ca2+]i of AICR in 
PASMCs from Hypx rat (n=12) compared to Nx control (n=9, p=0.04). * indicates that 
NA significantly suppressed peak [Ca2+]i of AICR in both Hypx (n=9) and Nx PASMCs 
(n=8) compared to its experimental control (p<0.001 and p=0.037, respectively). Note 
that inhibition of CD38 by NA lead to no difference in AICR between Hypx and Nx 
PASMCs. (C) The proportion of inhibition of peak [Ca2+] by NA (%decrease in 20 mM 
NA to control) in hypoxic PASMCs was significantly higher than the proportion in 






Figure 4.5. Hypoxic-induced enhancement of CD38 expression and AICR in 
PASMCs in vitro  (A) The expression of CD38 protein and mRNA in rat PASMCs 
isolated from normoxic rat cultured under normoxic (21% O2) and hypoxic conditions (2% 
O2) for 3 days. * indicates that CD38 protein and mRNA in Hypx PASMCs (n=6 and n=5, 
respectively) were significantly increased compared to the expression in Nx control 
PASMCs (n=6, p=0.025 and n=5, p=0.036, respectively). (B) Mean traces of Δ[Ca2+]i 
activated by 100 nM Ang II in Hypx and Nx PASMCs in the absence or presence of 20 
mM NA (left panel). Mean peak [Ca2+]i of AICR (middle panel). ** indicates 
significant enhancement of peak [Ca2+]i of AICR in Hypx PASMCs (n=15) compared to 
Nx control (n=14, p=0.02).* indicates that NA significantly suppressed the peak [Ca2+]i 
of AICR in both Hypx (n=7) and Nx PASMCs (n=6) (p<0.001 for both). Inhibition of 
CD38 by NA lead to no difference in the peak [Ca2+]i of AICR between Hypx and Nx 
PASMCs. The proportion of inhibition of peak [Ca2+] by NA (% decrease in 20 mM NA 
to control) in hypoxic PASMCs was significantly higher than the proportion in normoxic 




NFAT (10), Hif-1 (3),  NF-κB (2), and CREB-like (1)  motifs. 
 
Figure 4.6. DNA sequence of the putative 3.0 kbp 5'-UTR promoter region of rat 
CD38 gene   Transcription factor-binding sites are underlined. Note that there are 
multiple putative binding motifs for NFAT (10), HIF-1 (3), NF-κB (2) and CREB-like (1) 




Figure 4.7. Suppression of CH-induced CD38 upregulation by inhibition of 
calcineurin/NFAT-pathway   Western blot analysis for CD38 expression in PASMCs 
cultured under normoxic or hypoxic conditions for 3 days in the absence or presence of 3 
µM VIVIT (NFAT inhibitor) and 5 µM cyclosporin A (Cyc A) (n=5). * indicates that 
CD38 expression in PASMCs was significantly upregulated by hypoxic exposure for 3 
days in control (p=0.005), while the upregulation of CD38 was blocked in the presence of 
VIVIT or Cyc A. ** indicates that there was a significant difference between control and 
the VIVIT (p=0.015) or Cyc A (p=0.013) treated hypoxic cells. Note that hypoxia-
induced CD38 upregulation was blocked in the presence of VIVIT and Cyc A compared 




Figure 4.8. Increased expression of TPC1/2 in PA smooth muscle tissue of CH rats 
(10% O2)   (A) Western blot analysis of TPC1/2 protein in PA smooth muscle tissue 
from 4 week CH rats for. * indicates significant increase in both TPC1 and 2 in Hypx 
compared to Nx PA (n=6, p=0.031 and p=0.021, respectively). (B) Hypoxia-induced 
alteration of TPC1/2 protein and mRNA in PA tissues of rats after different period of 
hypoxic exposure. * indicates that TPC2 protein increased significantly in day 2, 3 and 7 
compared to day 0 (n=5, p=0.028, p=0.010, and p=0.033, respectively), whereas there 
was no significant increase in TPC1 protein in CH PAs. Note that mRNA expression of 
TPC1/2 was not altered by hypoxic exposure up to 1 week compared to the expression in 




 The major finding of this research project is that CH enhances the expression and 
activity of CD38 in rat PASMCs. While CD38 expression and activity in smooth muscle 
is known to be regulated by various cytokines and hormones such as TNF-α, endothelin-1, 
and Ang II [138,316,347], there is no systematic research on the regulation of CD38 in 
PASMCs with an emphasis on prolonged hypoxic exposure. This study first characterized 
the effect of CH on CD38 expression in the PAs of rats and found that CD38 expression 
was increased in a time-dependent manner in the first week of hypoxia exposure. The 
increase in CD38 expression was associated with enhanced CD38 enzymatic activity in 
PA smooth muscle and CD38-dependent AICR in PASMCs of CH rats. The effect of 
hypoxia on CD38 was reproduced in cultured PASMCs isolated from normoxic rats in 
vitro, indicating that these effects are due to the direct actions of hypoxia on PASMCs.  
Furthermore, CH-induced CD38 upregulation in hypoxic PASMCs was blocked by the 
inhibition of calcineurin or NFAT, suggesting that it underlies the calcineurin/NFAT 
pathway. Additionally, the expression of TPC2, which is the NAADP-sensitive Ca2+ 
release channel in the endolysosomes, were significantly increased in the PA smooth 
muscle of CH rat. These results provide the first evidence that CD38 may participate in 
the development of CHPH.  
 This study clearly demonstrated that CH induces CD38 expression in the PAs of 
rats. This effect of CH is time-dependent, with CD38 protein and mRNA increasing 
gradually in the first week of CH exposure, followed by a decline in the protein level 
after 3–4 week of CH, while the increased mRNA level remained unchanged. Since most 
of the changes in the development of PH, including increased PA pressure and vascular 
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remodeling, occur within the first week of hypoxia exposure [348,349,350], the 
upregulation of CD38 protein specifically in this period suggest that this could be related 
primarily to the progression, rather than the maintenance, of CHPH.  
 The significant increase found in the functional CD38 in the PA of week 1 
hypoxic rats is supported by the enhanced enzymatic activity of CD38. It is well 
established that CD38 is the major multi-catalytic NAD+-glycohydrolase (NADase), 
influencing the activity of cyclase, catalase, and hydrolase in the lungs [351] and other 
tissues [125]. We found that NADase activity was significantly increased in the PAs, 
while it decreased in the whole lung tissue, of hypoxic rats. Although we have not 
determined the individual enzymatic functions of the NADase activity due to its 
multifunctionality, the results clearly suggest that hypoxia alters the activity of CD38 
specifically in PA, independent of the other lung tissues.  These results, hence, suggest 
that CD38 upregulation in PA could be a unique characteristic in the development of 
CHPH.  
 In additional to NADase activity, we examined AICR to gauge the functional 
activity of CD38 in PASMCs. As shown in Chapter 3, Ang II induces CD38-dependent 
Ca2+ release in PASMCs. The magnitude of AICR in the PASMCs of week 4 CH rats 
was slightly but significantly increased, consistent with the moderate increase in CD38 
expression, suggesting that CD38 may contribute to enhanced Ca2+ release in CH 
PASMCs.  Consistent with CD38 expression data, AICR in the PASMCs of week 1 
hypoxic rats was greatly enhanced compared to that of the normoxic control. The 
augmentation of AICR is clearly related to the upregulation of CD38, because the 
difference between PASMCs of week 1 hypoxic and normoxic rats was completely 
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eliminated in the presence of the CD38 inhibitor NA, and the percent inhibition of AICR 
in PASMCs of the hypoxic rats was significantly greater than in those of the normoxic 
cells. It has been reported that members of the Ang II signaling pathway, including the 
level of Ang II and the Ang receptors, are elevated in animals and patients with 
pulmonary hypertension and that this is associated with the pathophysiology of CHPH 
[352,353,354,355]. The enhanced CD38-dependent Ca2+ release can provide an 
additional mechanism for the increased vasoreactivity to Ang II in CHPH.  Our previous 
studies found that other vasoactive agonists, such as ET-1 and integrin-ligands GRGDSP, 
also activate Ca2+ release through CD38 dependent mechanisms [114,122]. Our present 
results, hence, suggest that the increased CD38 expression may contribute to the 
enhanced agonist induced vasoreactivity in hypoxic PASMCs.  
 Hypoxia may exert its effect on CD38 expression by the direct modulation of 
gene expression in PASMCs or indirectly through other endocrinal or paracrinal agents/ 
factors released in the circulation and in the lung tissues [336]. Our observations that 
incubation of PASMCs from normoxic rats in 2% O2 for 3 days evoked a significant 
increase in CD38 protein and mRNA and that AICR was enhanced in hypoxic PASMCs 
clearly suggest that hypoxia alone can directly lead to CD38 upregulation, even through 
when the participation of other mechanisms under in vivo conditions are not excluded.    
 To date, there is no report on the regulation of CD38 expression by CH in 
PASMCs or any other tissue. However, previous studies have shown that several 
transcriptional factors, such as HIF and NFAT, play very important roles in gene 
regulation during CH [216,356,357,358]. We analyzed the 3.0 kbp 5'-UTR promoter 
region of CD38 in rats and found multiple putative binding sites for transcription factors 
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including HIF-1, NF-κB, CREB, and NFAT. Among the candidates, the putative binding 
motifs for NFAT are most abundant in that region, and a similar observation was made in 
the promoter regions of human and mouse CD38 genes (data not shown). This raises the 
interesting possibility that CD38 upregulation by hypoxia may be dependent on the 
NFAT-signaling pathway. NFAT is a transcription factor ubiquitously distributed in 
various cell types and regulated by dephosphorylation by calcineurin [359]. Indeed, 
NFATc3 plays a pivotal role in vascular development [360,361], cell proliferation, cell 
differentiation [362,363], and the characteristic of smooth muscle cell contractility 
[364,365]. Studies have also demonstrated that CH induces pulmonary arterial 
remodeling mediated, in part, by the activation of NFATc3 [366]. 
To test this possibility, we designed two different approaches to inhibit the NFAT 
pathway: inhibiting calcineurin with Cyc A and blocking the dephosphorylation site of 
NFAT with the specific peptide antagonist VIVIT. Both inhibitors mitigated the 
increased expression of CD38 by hypoxia in PASMCs. These results suggest that the 
hypoxic-induced upregulation of CD38 in PASMCs requires a functional activation of 
the NFAT signaling pathways. However, the possible roles of other hypoxia-related 
transcription factors such as HIF-1 and NF-κB in the regulation of CD38 expression in 
PASMCs require further investigation.   
 In addition to the enhancement of CD38 expression and activity, other members 
of the CD38-dependent Ca2+ release pathway, such as the RyRs and TPC channels, could 
also be affected by CH.  We have previously shown that NAADP evokes intracellular 
Ca2+ release via TPC1/2 of the endolysosomes and cross-activates RyRs to amplify Ca2+ 
release in PAMSCs [114]. In this study, we observed that TPC2 protein expression in PA 
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smooth muscle tissue was enhanced by CH exposure in a time-dependent manner during 
the early development of CHPH. Interestingly, CD38 expression was highest at 1 week 
and declined at 3–4 weeks of CH exposure, while elevated TPC1/2 protein levels were 
sustained.  In particular, TPC1 protein, which was not significantly increased at 1 week, 
was significantly increased after 4 weeks of CH. These data suggest that CH 
differentially regulates the components of the CD38-dependent mechanism at different 
stages in the development of CHPH.  
 Previous studies provided the evidence that the mechanism of CHPH 
development is complex and depends on many factors. Studies have established that an 
increased [Ca2+]i in PASMCs of CH animals stimulates pathophysiological changes 
including cell contraction, migration, and proliferation, eventually resulting in pulmonary 
vascular remodeling under CH. The current consensus on the alteration of Ca2+ levels in 
CH PASMCs is that it is due to the inhibition of the voltage-dependent K+ channel in 
exposure to CH, leading to membrane depolarization and an increase in [Ca2+]i [274,339]. 
It is recognized that CH also affects other Ca2+ influx mechanisms, including store-
operated and receptor-operated Ca2+ entry [238], mechanosensitive Ca2+ channels [37,39], 
and Ca2+ activated Cl- channels in PASMCs [75], leading to the elevation of [Ca2+]i. 
Moreover, recent studies have clearly demonstrated the differential roles of transient 
receptor potential (TRP) channels, including TRPC1, TRPC6 and TRPV4, in the 
development of CHPH and the alteration of vasoreactivity in PA from CH animals 
[37,38,367]. The diversity of [Ca2+]i the regulation mechanism in PASMC under CH is 
not fully understood, particularly for intracellular Ca2+ release. Our findings clearly 
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indicate that CH induces alterations of intracellular Ca2+ release mechanisms via an 
increase in the expression and activity of CD38 in PASMCs. 
  In conclusion, this study demonstrated that CH upregulates CD38 expression and 
activity in PASMCs and enhances the functional activity in response to Ang II. The 
upregulation of CD38 expression is mediated by Ca2+ dependent NFAT-pathways in 
PASMCs. These findings, therefore, provide novel information for improving our 
understanding of the mechanism for the development of CHPH. 
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 Ca2+ homeostasis is crucial for almost every physiological function and is 
maintained by different types of regulatory mechanisms in response to various 
environmental stimuli including hypoxic exposure. It is clearly recognized that [Ca2+]i is 
elevated in pulmonary arterial smooth muscle cells (PASMCs) from chronic hypoxia-
induced pulmonary hypertension (CHPH)  animals due to CH-induced increase in Ca2+ 
influx via functional and expressional enhancement of Ca2+ mobilization gated by 
membrane channels. Yet, the changes in the other part of Ca2+ regulation, intracellular 
Ca2+ release, have not been clearly established in PASMCs. An increasing number of 
studies have provided evidence that the multifunctional enzyme CD38 plays crucial roles 
in Ca2+ release, leading to multiple physiological responses in various cell types. 
However, the regulatory mechanism of CD38 has not been systematically established in 
PASMCs. Further, no study has investigated whether chronic hypoxia (CH) modulates 
the expression and activity of CD38 in PASMCs. 
  Based on these two questions, the work presented in this dissertation was 
proposed to describe the mechanisms of intracellular Ca2+ release mediated by CD38 in 
PASMCs and the alteration of the CD38 induced by CH exposure. The hypothesis and 
major findings for each aim are summarized as follows. 
 
1. The first hypothesis in this dissertation states that CD38 plays a role in 
intracellular Ca2+ in PASMCs and contributes to agonist-induced vasoconstriction in 
pulmonary arterial (PA) smooth muscle. CD38 is highly expressed in PA smooth muscle 
and PASMCs compared to other vascular smooth muscles. CD38 partially mediates 
angiotensin II (Ang II)-induced vasoconstriction in PA smooth muscle. Ang II-induced 
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intracellular Ca2+ release (AICR) in PASMCs is significantly reduced by 
pharmacological or by siRNA inhibition of CD38, indicating that AICR in PASMC is 
mediated by CD38. AICR is subsided with the inhibition of cADPR- and NAADP-
dependent Ca2+ release. In particular, suppression of these two Ca2+ release mechanisms 
is non-additive, indicating the inter-dependence between RyR- and NAADP-gated Ca2+ 
release in PASMCs. The Ang II-induced CD38-dependent intracellular Ca2+ release in 
PASMCs is mediated via PKC-NADPH oxidase 2-reactive oxygen species. For the first 
time, these results establish the signaling mechanism of CD38 activation in response to 
Ang II leading to Ca2+ release in PAMSCs. 
 
2. The second hypothesis of this dissertation states that the expression and activity of 
CD38 is altered by CH in PASMCs. CH induces the upregulation of CD38 expression in 
PASMCs in both in vivo and in vitro experiments. In particular, the activity of CD38 in 
PA smooth muscle from hypoxic rat was significantly increased compared to that from 
normoxic control rat, whereas the same activity in whole lung was decreased, suggesting 
a specific CD38 upregulation in hypoxic PA. AICR is significantly increased in hypoxic 
PASMCs both in vivo and in vitro. The difference between AICR in CH and normoxic 
PASMCs is completely abolished by the inhibition of CD38, indicating that CH 
stimulates the enhancement of CD38 activity in PASMCs. The CH-induced upregulation 
of CD38 expression in isolated PASMCs is inhibited by calcineurin/NFAT pathway, 
indicating that CH-induced CD38 upregulation in PASMCs is mediated by the 
calcineurin/NFAT-pathway. Beside, the NAADP-dependent Ca2+ channel TPC 1 and 
TPC 2 is increased in CH PA. Hence, for the first time, these results clearly support our 
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hypothesis that CH increases the expression and activity of CD38 and the CD38-
dependent Ca2+ release in PASMCs. 
 
 In conclusion, the results of this thesis reveal that CH triggers an increase in 
expression and activity of CD38, leading to alteration of Ca2+ homeostasis through 
increased Ca2+ in PASMCs. These results may suggest that CD38 is associated with 
development of CHPH and is a novel therapeutic target for pulmonary vasculature 
disease.  
 
Figure 5.1. Summary of the thesis research   CD38 in PASMCs plays an important 
role in the regulation of Ca2+ release from two different stores, RyR- and NAADP-
gated Ca2+ stores activated by cADPR and NAADP, respectively. The signaling 
mechanism of Ang II-induced CD38 activation is mediated by PKC-NOX2-ROS 
pathways. CH triggers enhancement of CD38 activity and expression. In particular, 





 While the experimental results revealed the novel aspects of expression and 
function of CD38 in PASMCs, particularly related to the alteration of Ca2+ signaling in 
the CHPH model, it also opens up many interesting directions for future research.  
 First, it is important to explore the detailed mechanism of how CH induces CD38 
upregulation beyond the calcineurin/NFAT-dependent pathway. For example, the role of 
hypoxia-inducible factor-1 (HIF-1) in the regulation of CD38 expression in PASMCs 
during CH has not been adequately described. It will be interesting to examine whether 
there is any interactions between HIF-1 and NFAT-pathways in the regulation of CD38 
in CH PASMCs. Further researches are required for establishing the translational 
mechanism of CH-induced upregulation of CD38 in PASMCs.  
 Secondly, future studies should provide evidence as to whether increased CD38 
expression and activity contribute to the alteration of PA properties such as myogenic 
tone and vasoreactivity in CHPH. It is well known that CH contributes to augmented 
vasoreactivity in mouse PA [75,211]. However, it is still unknown whether CD38 
contributes to changes in pulmonary vascular physiology through regulation of 
intracellular Ca2+ release during CHPH. These questions could be approached using the 
measurement of isometric contraction in PA smooth muscle tissues from CH rat in the 
presence of inhibitors for CD38-dependent mechanism (e.g., nicotinamide, 8-brom-
cADPR, and Ned-19), similar to the methods in chapter 2. In addition to the findings in 
chapter 4, such evidence could elucidate how the changes in mechanism of Ca2+ release 
potentiate and contribute to the development of vascular remodeling during CHPH. 
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 Finally, it is important to further explore the roles and mechanisms of other CD38 
agonists that are clearly associated with CHPH. ET-1 is a potential candidate and plays 
an important role in Ca2+ regulation during CH by altering the activity of Ca2+ regulatory 
molecules including augmentation of NCX and the voltage-gated Ca2+ channel, inhibition 
of voltage-gated K+ channels, and increased myofilament sensitivity in PASMCs 
[227,277,368]. Likewise, there has been no systematic research on the signaling 
mechanism of ET-1-induced activation of CD38 in PASMCs. Understanding the 
systematic mechanism of agonist-induced CD38 activation could elicit the novel aspects 
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